[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 65 of about 65
1. Boughey JC, Wagner J, Garrett BJ, Harker L, Middleton LP, Babiera GV, Meric-Bernstam F, Lucci A, Hunt KK, Bedrosian I: Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservation. Ann Surg Oncol; 2009 Jun;16(6):1606-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservation.
  • BACKGROUND: Patients with invasive lobular carcinoma (ILC) experience a lower pathological complete response rate to neoadjuvant chemotherapy than patients with invasive ductal carcinoma.
  • This study was intended to evaluate the impact of neoadjuvant chemotherapy in ILC on breast-conserving surgery (BCS) rates.
  • Surgical procedures and long-term outcomes were compared between patients receiving neoadjuvant chemotherapy and those receiving surgery first.
  • RESULTS: Neoadjuvant chemotherapy was administered to 84 patients; 200 patients underwent surgery first.
  • When controlled for initial tumor size, there was no difference (all p > 0.05) between the groups in terms of (1) the proportion of patients who underwent an initial attempt at BCS, (2) rate of failure of BCS or (3) the proportion of patients undergoing BCS as their final procedure.
  • CONCLUSION: The use of neoadjuvant chemotherapy does not increase the rates of breast conservation in patients with pure ILC.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Breast Neoplasms / drug therapy. Carcinoma, Lobular / drug therapy. Mastectomy, Segmental / statistics & numerical data
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Humans. Mastectomy / statistics & numerical data. Middle Aged. Neoadjuvant Therapy. Retrospective Studies

  • Genetic Alliance. consumer health - Invasive lobular carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19280264.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ NIHMS660874; NLM/ PMC4338983
  •  go-up   go-down


2. Morvan A, de Korvin B, Bouriel C, Carsin A, Tas P, Bendavid C, Dupré PF, Kerbrat P, Mesbah H, Poree P, Levêque J: [MRI evaluation of residual breast carcinoma after neoadjuvant chemotherapy]. J Radiol; 2010 Jun;91(6):693-9
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [MRI evaluation of residual breast carcinoma after neoadjuvant chemotherapy].
  • [Transliterated title] Cancer du sein traité par chimiothérapie néoadjuvante: évaluation du reliquat tumoral par l'IRM mammaire.
  • PURPOSE: This study aims to evaluate the sensibility and specificity of MRI in the detection and size measuring of residual breast cancer in patients treated with neoadjuvant chemotherapy before surgery.
  • PATIENTS AND METHODS: This is a retrospective study of 32 women, who underwent breast MRI before and after neoadjuvant treatment.
  • RESULTS: The sensibility of MRI to assess pathologic Complete Response (no invasive residual tumor) was excellent (100%) but the specificity was low (55,5%).
  • When MRI outcomes were compared with the presence or absence of invasive or in situ residual carcinoma, only one false negative case was noticed (one "in situ" residual tumor).
  • Underestimations of tumor size were due to non-continuous tumor regression or invasive lobular carcinoma or association of invasive carcinoma and intra ductal breast cancer.
  • Over estimations of tumor size were due to chemotherapy-induced changes.
  • CONCLUSION: MRI is a sensitive but poorly specific method to assess the pathological complete response after neoadjuvant chemotherapy.
  • Estimation of tumor size and detection of isolated residual in situ carcinoma are fare.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / drug therapy. Magnetic Resonance Imaging. Neoplasm, Residual / diagnosis
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Neoadjuvant Therapy. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20808270.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


3. Akashi-Tanaka S, Fukutomi T, Watanabe T, Katsumata N, Nanasawa T, Matsuo K, Miyakawa K, Tsuda H: Accuracy of contrast-enhanced computed tomography in the prediction of residual breast cancer after neoadjuvant chemotherapy. Int J Cancer; 2001 Feb 20;96(1):66-73
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of contrast-enhanced computed tomography in the prediction of residual breast cancer after neoadjuvant chemotherapy.
  • Determination of the extent of residual disease after neoadjuvant chemotherapy is sometimes inaccurate by conventional diagnostic methods.
  • The purpose of this study was to evaluate the accuracy of contrast-enhanced computed tomography (CE-CT) in depicting the extent of residual carcinomas.
  • Fifty-seven patients with breast carcinomas of 3 cm diameter or more received neoadjuvant chemotherapy with four cycles of AT (doxorubicin and docetaxel).
  • Enhancement patterns on CE-CT were classified into multiple spots, tumor and spots, solid tumor type, and no enhancement.
  • When all types of cancers were included in the analysis, clinical examination showed the best correlation with the pathology of the extent of residual carcinomas.
  • However, except in invasive lobular carcinoma (ILC) and inflammatory breast carcinoma (IBC), CE-CT showed the best correlation (R insertion mark2 = 0.537).
  • More than half of the residual microcalcifications on MMG after neoadjuvant chemotherapy suggested residual viable tumor.
  • In conclusion, CE-CT is the most accurate noninvasive technique for identifying the extent of the residual carcinoma after neoadjuvant chemotherapy if cases of IBC and ILC are excluded.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / drug therapy. Chemotherapy, Adjuvant. Paclitaxel / analogs & derivatives. Taxoids. Tomography, Emission-Computed / methods
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Doxorubicin / administration & dosage. Female. Humans. Mammography. Middle Aged. Reproducibility of Results

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11241331.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 80168379AG / Doxorubicin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


Advertisement
4. Akiyama F, Horii R: Therapeutic strategies for breast cancer based on histological type. Breast Cancer; 2009;16(3):168-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic strategies for breast cancer based on histological type.
  • Breast cancer has various histological types that reflect not only morphological features but also biological characteristics.
  • Therefore, it is not an exaggeration to say that breast cancers of different histological types are different diseases.
  • It is generally accepted that the histological types of breast cancer are clinically significant because they serve as prognosticators and as the common language for improving the accuracy of clinical diagnosis.
  • It is necessary to diagnose breast cancer at the level of not only histological findings by needle biopsy, but also the histologic type based on diagnostic imaging and cytological diagnosis.
  • From the viewpoint of treatment, preoperative drug therapy is being performed more frequently to shrink tumors before breast-conserving therapy or to determine treatment sensitivity.
  • The prognosis is favorable for patients who respond completely or patients in whom interstitial infiltration is completely eliminated histopathologically, and, as a result, it is important to assess therapeutic efficacy clinically and pathologically.
  • Past experience has shed some light on differentiating cancers responsive to drug therapy from those unresponsive to drug therapy, as well as differentiating cancers in which therapeutic efficacy can be easily ascertained from those in which therapeutic efficacy cannot be easily ascertained.
  • Preoperative drug therapy can be planned by making a histological diagnosis based on needle biopsy findings.
  • Preoperative drug therapy is not indicated for noninvasive carcinoma and papillotubular carcinoma (invasive carcinoma with predominant intraductal components).
  • While complete loss of interstitial infiltration can be expected with solid-tubular carcinoma, it cannot be expected with other histological types, such as invasive lobular carcinoma, adenoid cystic carcinoma, or metaplastic carcinoma (squamous-cell carcinoma and spindle-cell carcinoma).
  • On therapeutic response assessment, the clinical and pathological findings generally match for solid-tubular carcinoma but not for scirrhous carcinoma and invasive lobular carcinoma.
  • With mucinous carcinoma, mucus accumulation can remain, even though most cancer cells disappear; as a result, assessment based on tumor diameter changes is difficult.
  • Histological diagnosis is also significant from the viewpoint of drug sensitivity, and it is important to maintain the accuracy of histological diagnosis.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma / drug therapy
  • [MeSH-minor] Female. Humans. Neoadjuvant Therapy. Prognosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19479319.001).
  • [ISSN] 1880-4233
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


5. Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau SW, Broglio K, Theriault RL, Valero V, Buzdar AU, Kuerer H, Buchholz TA, Hortobagyi GN: Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol; 2005 Jan 1;23(1):41-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes.
  • PURPOSE: To investigate the impact of histologic type invasive lobular carcinoma (ILC) versus invasive ductal carcinoma (IDC) on response to primary chemotherapy (PC) and long-term outcome.
  • PATIENTS AND METHODS: The study included 1,034 patients with stage II and III breast cancer who participated in six clinical trials of PC at our institution between 1985 and 2002.
  • Pathologic complete response (pCR) was defined as no evidence of invasive disease in the breast and axillary lymph nodes.
  • At a median follow-up time of 70 months, ILC patients tended to have longer recurrence-free survival (P = .004) and overall survival (P = .001).
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / mortality. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / mortality
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Axilla. Bridged Compounds / therapeutic use. Carcinoma, Ductal / drug therapy. Carcinoma, Ductal / mortality. Carcinoma, Ductal / pathology. Disease-Free Survival. Humans. Lymph Nodes / pathology. Middle Aged. Neoplasms, Hormone-Dependent / drug therapy. Neoplasms, Hormone-Dependent / mortality. Taxoids / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Invasive lobular carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Sep 20;23(27):6796; author reply 6796-7 [16170189.001]
  • [ErratumIn] J Clin Oncol. 2013 Aug 10;31(23):2977. Buccholz, Thomas A [corrected to Buchholz, Thomas A]
  • (PMID = 15625359.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bridged Compounds; 0 / Taxoids; 1605-68-1 / taxane
  •  go-up   go-down


6. Katz A: Does neoadjuvant/adjuvant chemotherapy change the natural history of classic invasive lobular carcinoma? J Clin Oncol; 2005 Sep 20;23(27):6796; author reply 6796-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does neoadjuvant/adjuvant chemotherapy change the natural history of classic invasive lobular carcinoma?
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / pathology. Neoadjuvant Therapy / methods
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Mastectomy / methods. Neoplasm Invasiveness / pathology. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Assessment. Survival Analysis

  • Genetic Alliance. consumer health - Invasive lobular carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Clin Oncol. 2005 Jan 1;23(1):41-8 [15625359.001]
  • (PMID = 16170189.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comment; Comparative Study; Letter
  • [Publication-country] United States
  •  go-up   go-down


7. Wagner J, Boughey JC, Garrett B, Babiera G, Kuerer H, Meric-Bernstam F, Singletary E, Hunt KK, Middleton LP, Bedrosian I: Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer. Am J Surg; 2009 Sep;198(3):387-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer.
  • BACKGROUND: Optimal surgical management of patients with invasive lobular carcinoma (ILC) who undergo neoadjuvant chemotherapy (NAC) is unknown.
  • RESULTS: Margin positivity rates after the final operative procedure were similar between the NAC and surgery-first group (P > .05).
  • At a median follow-up of 3.1 years, 1 patient in the NAC group and 2 in the surgery-first group developed LR (P = 1.0).
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / surgery. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Chi-Square Distribution. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Neoplasm, Residual / drug therapy. Neoplasm, Residual / pathology. Neoplasm, Residual / surgery. Reoperation. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19362281.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS661346; NLM/ PMC4355914
  •  go-up   go-down


8. Anwar IF, Down SK, Rizvi S, Farooq N, Burger A, Morgan A, Hussien MI: Invasive lobular carcinoma of the breast: should this be regarded as a chronic disease? Int J Surg; 2010;8(5):346-52
MedlinePlus Health Information. consumer health - Mastectomy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive lobular carcinoma of the breast: should this be regarded as a chronic disease?
  • BACKGROUND: The surgical treatment of patients with invasive lobular carcinoma is still controversial due to its different clinical and pathological features.
  • AIM OF THE STUDY: To study the implications and outcome of extending the follow-up period of patients treated for invasive lobular carcinoma.
  • Thirty-three patients were excluded as they had primary hormonal therapy.
  • RESULTS: Seventy-nine patients (33.6%) had breast conservation surgery (group I), which was followed by re-excision due to positive margins in 23 patients (29%), and 156 patients (66.3%) had mastectomy (group II).
  • Forty-eight patients (17.9%) developed local recurrence [27 (34%) in group I and 21 (13.4%) in group II, P=0.0005] after a median follow-up period of 167.8 months.
  • The mean time to local recurrence was 127 (range 24-196) months.
  • Univariate analysis showed that the type of surgery, margin status, adjuvant radiotherapy and chemotherapy significantly affected local recurrence (P=0.0005, 0.02, 0.04 and 0.05 respectively).
  • Cox regression analysis showed that the only factor affected local recurrence was the type of surgery (relative risk 2.43, 95% confidence interval 1.22-4.83, P=0.01) The overall survival was 99.3 months (78.2%).
  • CONCLUSION: Local recurrence may be a late event in patients treated for invasive lobular carcinoma of the breast and extended follow-up may be considered.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Lobular / secondary. Mastectomy / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chronic Disease. Female. Follow-Up Studies. Great Britain / epidemiology. Humans. Incidence. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / epidemiology. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate / trends. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Invasive lobular carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20420942.001).
  • [ISSN] 1743-9159
  • [Journal-full-title] International journal of surgery (London, England)
  • [ISO-abbreviation] Int J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Katz A, Saad ED, Porter P, Pusztai L: Primary systemic chemotherapy of invasive lobular carcinoma of the breast. Lancet Oncol; 2007 Jan;8(1):55-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary systemic chemotherapy of invasive lobular carcinoma of the breast.
  • Invasive lobular carcinoma is the second most frequent histological type of breast cancer and its incidence is increasing.
  • Invasive lobular carcinoma is almost invariably positive for the oestrogen receptor and, when compared with invasive ductal carcinoma, it is typically of a lower grade.
  • Even though invasive lobular carcinoma represents a distinct clinical entity, the same criteria used for invasive ductal carcinoma are currently applied to establish the need for primary or adjuvant systemic chemotherapy.
  • We reviewed randomised trials of neoadjuvant and adjuvant chemotherapy and noted that insufficient evidence is available to support or withhold use of chemotherapy in patients with invasive lobular carcinoma.
  • Thus, the benefit from systemic chemotherapy for individuals with this form of breast disease is unclear.
  • Invasive lobular carcinoma deserves to be investigated separately in prospective clinical trials to define the best treatment and prevention strategies.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Lobular / drug therapy. Neoplasm Invasiveness / pathology
  • [MeSH-minor] Chemotherapy, Adjuvant. Clinical Trials as Topic. Female. Humans. Incidence

  • Genetic Alliance. consumer health - Invasive lobular carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17196511.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 75
  •  go-up   go-down


10. Shien T, Akashi-Tanaka S, Yoshida M, Hojo T, Iwamoto E, Miyagawa K, Kinoshita T: Usefulness of preoperative multidetector-row computed tomography in evaluating the extent of invasive lobular carcinoma in patients with or without neoadjuvant chemotherapy. Breast Cancer; 2009;16(1):30-6
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of preoperative multidetector-row computed tomography in evaluating the extent of invasive lobular carcinoma in patients with or without neoadjuvant chemotherapy.
  • BACKGROUND: The present study was conducted to assess the clinical usefulness of multidetector-row CT (MDCT) in determining the extent of invasive lobular carcinoma (ILC) and especially the extent of residual tumor after neoadjuvant chemotherapy (NAC).
  • RESULTS: The findings of primary ILC obtained by MDCT showed that the carcinoma was the non-localized type rather than the localized type in 63% of the subjects.
  • In addition, with regard to the pattern of time-sequential contrast enhancement, the persistent pattern (in which tumor enhancement is strong in the late phase rather than in the early phase) was observed in 46% of the subjects, and the plateau pattern (in which contrast enhancement is weak in both the early phase and the late phase) was observed in 38% of the subjects.
  • Assessment of the extent of carcinoma showed that the diagnostic accuracy of MDCT was 79%, as compared with 71% for either ultrasound or mammography.
  • Assessment of the extent of carcinoma after NAC also showed that the diagnostic accuracy of MDCT was 71%, as compared with 48% for ultrasound and 53% for mammography, indicating that MDCT provided the highest accuracy.
  • In addition, MDCT was found to be useful for determining the extent of carcinoma, and the diagnostic accuracy of MDCT, especially in determining the extent of carcinoma after NAC, was much higher than that of ultrasound or mammography.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Lobular / pathology. Preoperative Care. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Lymph Node Excision. Mammography. Mastectomy. Mastectomy, Segmental. Middle Aged. Neoadjuvant Therapy. Retrospective Studies. Ultrasonography

  • Genetic Alliance. consumer health - Invasive lobular carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18360805.001).
  • [ISSN] 1880-4233
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


11. Konishi K, Hasegawa N, Kaneko H, Iimura Y, Shoji Y, Kawabata M: [Two cases of breast cancer responding to primary systemic chemotherapy containing trastuzumab without surgery]. Gan To Kagaku Ryoho; 2010 Jan;37(1):115-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of breast cancer responding to primary systemic chemotherapy containing trastuzumab without surgery].
  • The first case was a 40-year-old woman who was referred to our hospital with a complaint of left breast tumor.
  • She was diagnosed as invasive ductal carcinoma (T2N0M0, Stage IIA).
  • After primary systemic chemotherapy with 6 courses of 5-fluorouracil+epirubicin+cyclophosphamide(FEC)and 3 courses of weekly paclitaxel (PTX)+trastuzumab, the efficacy of chemotherapy was judged as a complete response (CR).
  • After chemotherapy, radiotherapy for her left breast was performed without surgery.
  • The efficacy of chemotherapy was judged as a partial response (PR).
  • The second case was a 26-year-old woman referred to our hospital with a complaint of right breast tumor.
  • She was diagnosed as invasive lobular carcinoma (T2N0M0, Stage IIA).
  • After primary systemic chemotherapy with 4 courses of FEC and 6 courses of docetaxel+trastuzumab, the efficacy of chemotherapy was judged as CR.
  • After chemotherapy, radiotherapy for her right breast was performed without surgery.
  • The efficacy of treatment was judged as CR for 15 months.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Lobular / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Combined Modality Therapy. Female. Humans. Trastuzumab

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20087043.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; P188ANX8CK / Trastuzumab
  •  go-up   go-down


12. Mathieu MC, Rouzier R, Llombart-Cussac A, Sideris L, Koscielny S, Travagli JP, Contesso G, Delaloge S, Spielmann M: The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer; 2004 Feb;40(3):342-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile.
  • The aim of this study was to determine the chemosensitivity of infiltrating lobular breast carcinoma (ILC) in comparison with infiltrating ductal carcinoma (IDC).
  • Between 1987 and 1995, 457 patients with invasive T2>3 cm-T4 breast carcinomas were treated with primary chemotherapy (CT), surgery, radiation therapy.
  • Clinical response, the possibility of breast preservation, pathological response and survival were evaluated according to the histological type.
  • ILC was an independent predictor of a poor clinical response (P=0.02) and ineligibility for breast-conserving surgery after neoadjuvant chemotherapy (P=0.03).
  • Preoperative CT did not allow a high rate of conservative treatment for ILC and therefore the use of neoadjuvant CT for ILC patients should be questioned.
  • [MeSH-major] Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Lobular / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Immunohistochemistry. Mastectomy / methods. Middle Aged. Survival Analysis. Treatment Failure

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14746851.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


13. Gonzalez-Angulo AM, Kau SW, Broglio K, Buzdar AU, Theriault RL, Valero V, Sneige N, Frye D, Hortobagyi GN, Cristofanilli M: Invasive lobular carcinoma (ILC) "classic type": Distinct clinical features. J Clin Oncol; 2004 Jul 15;22(14_suppl):663

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive lobular carcinoma (ILC) "classic type": Distinct clinical features.
  • : 663 Background: classic ILC represents 5-10% of all primary breast cancers (BC).
  • Induction chemotherapy (IC) is used to downstage tumors and facilitate breast conservative surgery.
  • All pts received anthracycline-based chemotherapy and 246 pts (23.8%) also received a taxane. pCR was defined as no evidence of invasive BC in the breast and axillary lymph nodes.
  • The lobular group tended to be older (med, 53 vs. 47 yrs), have more HR positive tumors, (92% vs. 62%) lower nuclear grade (16% vs. 56% grade 3), and higher stage at diagnosis (10% vs. 0% were IIIB and IIIC).
  • CONCLUSION: ILC is a distinct histological type of breast cancer characterized by better outcome when compared to IDC in spite of the low pCR rate after IC.
  • The role of primary hormonal therapy should be assessed in ILC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28017095.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Khosravi-Shahi P, Izarzugaza Peron Y, Perez-Manga G: Low pathologic complete response (pCR) rate to neoadjuvant chemotherapy in invasive lobular carcinoma of breast: Analysis of subgroup of four phase II trials. J Clin Oncol; 2009 May 20;27(15_suppl):601

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low pathologic complete response (pCR) rate to neoadjuvant chemotherapy in invasive lobular carcinoma of breast: Analysis of subgroup of four phase II trials.
  • : 601 Background: Pathologic complete response (pCR) after preoperative chemotherapy (PCT) is associated with better outcome in locally advanced breast cancer (LABC).
  • METHODS: Patients (p) with histologically confirmed lobular carcinoma (LC), including in four phase II trials (AT, ATX, TXH, and BTX) conducted in our center, were eligible.
  • Radiotherapy (RT) and hormone therapy (Ht) were allowed after surgery.
  • Secondary endpoints were: clinical response rate (CRR), breast conservative surgery rate (BCSR), pathologic tumoral size (pTS), disease-free survival (DFS), and overall survival (OS).
  • Sixteen ps had LC (16/185 = 8.65%): median age = 50 y (38-66); premenopausal = 56.2%; left breast = 56.2%; median clinical (c) tumor size = 5 cm (3-6); stage:IIA = 6.7%; IIB = 26.7%; IIIA = 33.3%; IIIB = 33.3%; T:cT3 = 50%; cT4 = 28.6%; cN+ = 71.4% (median pN = 2 [0-32]); grade: G2 = 60%, G3 = 40%; ER+ = 78.6%; PgR+ = 64.3%; HER-2+ = 6.25%; phenotype by IHC: Luminal (HR+/HER-2-) = 75% (12/16); Luminal/HER-2+ (HR+/HER-2+) = 6.25%; triple negative (3/16) = 18.75%; p53+ = 25%; EGFR negative = 90%; median Ki-67 = 20% (5-70); adjuvant trastuzumab (H) = 6.25%; RT = 60%, median dose = 50Gy; Ht = 78.6% (tamoxifen = 55%; AI = 45%); type of PCT: docetaxel (T), capecitabine (X), and H (TXH) = 1p (6.2%); doxorubicin (A), T, and X (ATX) = 5 ps (31.2%); bevacizumab, T, and X (BTX) = 5 ps (31.2%); AT = 5 ps (31.2%); median of 5 cycles (2-6).
  • Primary End-Point: Only 1 p (6.25%) had pCR in breast and nodes, and another p had a pCR only in breast, but not in nodes (pCR in breast = 2/16).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961466.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Silberfein EJ, Hunt KK, Broglio K, Shen J, Sahin A, Le-Petross H, Oh J, Litton J, Hwang RF, Mittendorf EA: Clinicopathologic factors associated with involved margins following breast conserving surgery for invasive lobular carcinoma (ILC). J Clin Oncol; 2009 May 20;27(15_suppl):e11528

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic factors associated with involved margins following breast conserving surgery for invasive lobular carcinoma (ILC).
  • This has resulted in difficulty obtaining negative margins at the time of breast conserving surgery.
  • Clinical data including radiographic appearance, biopsy method, initial surgical procedure (segmental vs. total mastectomy), and use of neoadjuvant chemotherapy were noted.
  • RESULTS: 110 (52%) patients underwent total mastectomy and 101 (48%) underwent segmental mastectomy as their initial procedure.
  • Breast conserving surgery was ultimately successful in 86 patients (85%).
  • CONCLUSIONS: The majority of patients with ILC can undergo successful breast conserving surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964633.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Cocquyt VF, Blondeel PN, Depypere HT, Praet MM, Schelfhout VR, Silva OE, Hurley J, Serreyn RF, Daems KK, Van Belle SJ: Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma. Eur J Surg Oncol; 2003 May;29(4):361-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma.
  • AIM: Preoperative chemotherapy (PCT) is used in primary breast cancer, to facilitate breast conservative surgery (BCS).
  • Biologic markers are needed to individualize treatment.
  • PATIENTS AND METHODS: One hundred and thirty-five patients with breast carcinoma were treated with PCT, followed by surgery and adjuvant therapy.
  • Clinical response and pathological complete response (pCR), biological markers and type of surgery were compared between invasive ductal (IDC) and invasive lobular carcinoma (ILC).
  • After PCT, patients with large ILC should preferably be offered mastectomy with immediate breast reconstruction.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Lobular / drug therapy
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Mastectomy, Segmental. Methotrexate / administration & dosage. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Prospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • Genetic Alliance. consumer health - Invasive lobular carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12711290.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate; CAF protocol; CMF protocol
  •  go-up   go-down


17. Peintinger F, Kuerer HM, Anderson K, Boughey JC, Meric-Bernstam F, Singletary SE, Hunt KK, Whitman GJ, Stephens T, Buzdar AU, Green MC, Symmans WF: Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy. Ann Surg Oncol; 2006 Nov;13(11):1443-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy.
  • BACKGROUND: Residual tumor size after neoadjuvant chemotherapy is an important consideration in surgical planning.
  • METHODS: Tumor size was evaluated by physical examination, mammography, and sonography at diagnosis and before surgery in 162 breast cancer patients who received neoadjuvant chemotherapy.
  • The effect of invasive lobular carcinoma, high nuclear grade, hormone receptor positivity, and the presence of an extensive intraductal component on the accuracy of mammography and sonography in predicting pathologic residual tumor size was analyzed.
  • Multivariate analysis showed that pathologic residual tumor size was underestimated for lobular carcinoma and overestimated for poorly differentiated tumors.
  • CONCLUSIONS: The combination of mammography and sonography has a high accuracy in predicting pCR after neoadjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / radiography. Breast Neoplasms / ultrasonography. Mammography. Ultrasonography, Mammary
  • [MeSH-minor] Adult. Aged. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Lobular / diagnosis. Carcinoma, Lobular / drug therapy. Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Neoadjuvant Therapy. Neoplasm Invasiveness / pathology. Neoplasm Staging

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17028770.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


18. Bassarova AV, Sedloev T, Christova SL, Trifonov DY, Nesland JM: Invasive lobular carcinoma in a hypoplastic breast. Ultrastruct Pathol; 2002 Nov-Dec;26(6):411-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive lobular carcinoma in a hypoplastic breast.
  • Breast hypoplasia is encountered as part of genetic syndromes or as a result of iatrogenic factors.
  • The incidence of this malformation and the occurrence of breast carcinoma in such cases are unknown.
  • The authors present a 66-year-old patient with a severe breast hypoplasia and invasive lobular carcinoma.
  • The advanced clinical stage required neoadjuvant chemotherapy.
  • The pathological report revealed an infiltrating lobular carcinoma with combined classical and alveolar growth and with minor morphological changes after the chemotherapy.
  • The tumor expressed a high bcl-2/low bax ratio and lacked p53 immunoreactivity, which could explain the resistance to neoajuvant therapy.
  • To the authors' knowledge this is the first case of an invasive lobular carcinoma in a hypoplastic breast reported in the English literature.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Lobular / pathology
  • [MeSH-minor] Aged. Breast / pathology. Female. Humans. Immunohistochemistry. Mastectomy, Modified Radical. Neoplasm Invasiveness / pathology


19. Cocquyt VF, Schelfhout VR, Blondeel PN, Depypere HT, Daems KK, Serreyn RF, Praet MM, Van Belle SJ: The role of biological markers as predictors of response to preoperative chemotherapy in large primary breast cancer. Med Oncol; 2003;20(3):221-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of biological markers as predictors of response to preoperative chemotherapy in large primary breast cancer.
  • The aim of this prospective study was to evaluate biological markers, their correlation with response and outcome, and the change in these markers under the influence of preoperative chemotherapy (PCT) in patients with a large primary breast cancer.
  • One hundred and thirty-five women were treated with PCT, followed by locoregional therapy and adjuvant treatment.
  • Forty-four percent of the patients could be offered breast-conserving surgery (BCS).
  • No local recurrence (LR) has developed following BCS.
  • Invasive ductal carcinoma (IDC) was more frequently ER-negative and HER-2-positive than invasive lobular carcinoma (ILC).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Breast Neoplasms / drug therapy. Breast Neoplasms / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 May;17(5):1474-81 [10334533.001]
  • [Cites] Br J Cancer. 1996 Nov;74(9):1458-65 [8912545.001]
  • [Cites] Breast Cancer Res Treat. 1997 Jul;44(3):185-92 [9266097.001]
  • [Cites] N Engl J Med. 1994 May 5;330(18):1260-6 [7908410.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):1974-82 [10561247.001]
  • [Cites] J Clin Oncol. 1992 Jul;10(7):1049-56 [1351538.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):93-100 [9440728.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2651-8 [9704715.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2334-56 [11304787.001]
  • [Cites] Ann Oncol. 2000 Aug;11(8):1057-9 [11038046.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2672-85 [9704717.001]
  • [Cites] Int J Cancer. 1993 Sep 30;55(3):429-35 [8397164.001]
  • [Cites] Eur J Cancer. 2001 Jan;37 Suppl 1:S11-7 [11167086.001]
  • [Cites] Int J Cancer. 1995 May 4;61(3):301-5 [7729938.001]
  • [Cites] Acta Oncol. 1992;31(2):125-30 [1622626.001]
  • [Cites] J Clin Oncol. 2001 Nov 15;19(22):4224-37 [11709566.001]
  • [Cites] Ann Oncol. 1999 Sep;10(9):1011-21 [10572598.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2505-12 [11289122.001]
  • [Cites] Br J Cancer. 1997;76(7):917-22 [9328152.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3817-27 [11559719.001]
  • [Cites] Int J Cancer. 1999 Dec 22;84(6):580-6 [10567902.001]
  • [Cites] Lancet. 1998 Sep 19;352(9132):930-42 [9752815.001]
  • [Cites] J Natl Cancer Inst. 1998 Nov 4;90(21):1601-8 [9811309.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):460-9 [10080586.001]
  • [Cites] Ann Oncol. 2000 Jun;11(6):647-63 [10942052.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):17-23 [11773149.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3058-63 [10506600.001]
  • [Cites] Nat Med. 1996 Jul;2(7):811-4 [8673929.001]
  • [Cites] Clin Cancer Res. 1997 Apr;3(4):593-600 [9815725.001]
  • [Cites] J Natl Cancer Inst. 1993 Feb 3;85(3):200-6 [8423624.001]
  • [Cites] Int J Cancer. 1998 Feb 20;79(1):27-33 [9495354.001]
  • [Cites] Mol Endocrinol. 1990 Sep;4(9):1327-35 [2172799.001]
  • (PMID = 14514971.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, ErbB-2; EC 3.4.23.5 / Cathepsin D
  •  go-up   go-down


20. Braud AC, Levy E, Feuilhade F, Otmezguine Y, Calitchi E, Kirova Y, Le Bourgeois JP: Combination of vinorelbine, epirubicin, and cyclophosphamide as neoadjuvant chemotherapy for locally advanced breast cancer: phase II study. Am J Clin Oncol; 2002 Jun;25(3):303-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination of vinorelbine, epirubicin, and cyclophosphamide as neoadjuvant chemotherapy for locally advanced breast cancer: phase II study.
  • Achievement of a pathologic complete response after primary chemotherapy in breast cancer can predict long-term outcome.
  • We have investigated a combination of epirubicin, cyclophosphamide, and vinorelbine as neoadjuvant chemotherapy in locally advanced breast cancer (LABC).
  • From January 1997 to May 1999, 30 chemonaive patients were treated (T2 or T3 histologically proven invasive breast carcinoma).
  • Treatment was vinorelbine 25 mg/m2 day 1 and day 3, epirubicin 30 mg/m2/d, days 1 to 3, cyclophosphamide 350 mg/m2/d, days 1 to 3, every 14 days for 4 courses.
  • Median age: 48 years (range: 28-66 years); 26 had ductal invasive carcinoma and 4 lobular invasive carcinoma; median tumor size: 7 cm; median number of induction cycles: four.
  • Twenty-nine patients had surgical treatment.
  • Pathologic response rate was complete response in 32% (no residual tumor), in situ carcinoma: 11%, invasive or unchanged tumor remaining: 57%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Epirubicin / administration & dosage. Humans. Middle Aged. Neoadjuvant Therapy. Survival Analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12040294.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 5V9KLZ54CY / Vinblastine; 8N3DW7272P / Cyclophosphamide; Q6C979R91Y / vinorelbine
  •  go-up   go-down


21. Kashiwagi S, Kawajiri H, Noda S, Takashima T, Onoda N, Nakata B, Kato Y, Ishikawa T, Hirakawa K: [A case of multicentric breast cancer in which an effect of neoadjuvant chemotherapy had a disparity]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2775-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of multicentric breast cancer in which an effect of neoadjuvant chemotherapy had a disparity].
  • A 61-year-old woman was visited our hospital for a left breast tumor.
  • Ultrasonography (US) demonstrated two tumors comprising a tumor 3.3 cm in diameter in the A area and another one 0.9 cm in diameter in the C area of the left breast, and US-guided core needle biopsy (CNB) was performed.
  • The histological findings showed invasive ductal carcinoma, ER (+)/PR (-)/HER2 (+) in the A lesion and ER (+)/PR (+)/HER2 (-) in the C lesion.
  • At this point in time, US demonstrated a new tumor 1.9 cm in diameter in the outside C area of the left breast, and CNB was performed.
  • The histological findings showed invasive ductal carcinoma, ER (+)/PR (+)/HER2 (-) in the outside C lesion.
  • Chemotherapy was estimated as PD, and an operation was performed (Bt + Ax).
  • Histopathological examination showed pCR in the A lesion, invasive lobular carcinoma in the C lesion and solid-tubular carcinoma in the outside C new lesion.
  • Depend on each subtype, HER2/new targeting trastuzumab therapy, radiation therapy and ER/PR targeting hormone therapy were tried as a post operative treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / pathology. Neoadjuvant Therapy. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Cyclophosphamide / therapeutic use. Epirubicin / therapeutic use. Female. Fluorouracil / therapeutic use. Humans. Middle Aged

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224709.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; FEC protocol
  •  go-up   go-down


22. Nihon-Yanagi Y, Park Y, Ooshiro M, Aoki H, Suzuki Y, Hiruta N, Kameda N, Katoh R: A case of recurrent invasive lobular carcinoma of the breast found as metastasis to the duodenum. Breast Cancer; 2009;16(1):83-7
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of recurrent invasive lobular carcinoma of the breast found as metastasis to the duodenum.
  • A 57-year-old woman underwent modified radical mastectomy for cancer of the left breast (stage IIB) in February 2004.
  • Invasive lobular carcinoma was diagnosed on histopathological examination.
  • The patient received postoperative chemotherapy and endocrine therapy on an outpatient basis and was observed.
  • In August 2005, anorexia developed.
  • Computed tomography (CT) of the abdomen revealed an enlarged duodenum and dilated intrahepatic biliary and pancreatic ducts.
  • A biopsy yielded a diagnosis of poorly differentiated adenocarcinoma.
  • Duodenal carcinoma was suspected, and a pancreatoduodenectomy was performed.
  • Duodenal metastasis from invasive lobular carcinoma was diagnosed on postoperative histopathological examination.
  • In March 2006, bilateral hydronephrosis apparently caused by peritoneal metastasis developed, and she subsequently died.
  • Invasive lobular carcinoma is characterized by the development of gastrointestinal metastases and is rarely detected before autopsy.
  • We describe our experience with a patient in whom invasive lobular carcinoma of the breast with metastasis to the duodenal wall was definitively diagnosed on laparotomy.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Lobular / pathology. Carcinoma, Lobular / secondary. Duodenal Neoplasms / secondary. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Invasive lobular carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18386118.001).
  • [ISSN] 1880-4233
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


23. Kubo M, Jida M, Yamane M, Miyatani K, Udaka T, Sogabe O, Maeda H, Mizuta M, Shirakawa K: [Improved quality of life in a patient with carcinomatous meningitis from invasive lobular carcinoma treated with intrathecal MTX and Ara-C in combination with systemic docetaxel]. Gan To Kagaku Ryoho; 2005 Dec;32(13):2097-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Improved quality of life in a patient with carcinomatous meningitis from invasive lobular carcinoma treated with intrathecal MTX and Ara-C in combination with systemic docetaxel].
  • Carcinomatous meningitis from breast cancer is rare and has a poor prognosis with a life expectancy of approximately 80 days.
  • We performed intrathecal MTX and Ara-C in combination with systemic docetaxel treatments in the patient, a 44-year-old woman with carcinomatous meningitis from invasive lobular carcinoma previously treated with anthracycline and paclitaxel.
  • Although the patient died 128 days after the onset, intrathecal chemotherapy in combination with systemic docetaxel reduced the number of malignant cells and induced degeneration of the cells in CSF, resulting in improved quality of life.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / pathology. Carcinoma, Lobular / pathology. Meningeal Neoplasms / pathology. Meningitis / drug therapy. Quality of Life
  • [MeSH-minor] Adult. Cerebrospinal Fluid / cytology. Cytarabine / administration & dosage. Drug Administration Schedule. Female. Humans. Injections, Spinal. Methotrexate / administration & dosage. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Invasive lobular carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Meningitis.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16352935.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 04079A1RDZ / Cytarabine; 15H5577CQD / docetaxel; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


24. Goldstein NS, Decker D, Severson D, Schell S, Vicini F, Margolis J, Dekhne NS: Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer; 2007 Oct 15;110(8):1687-96
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy.
  • BACKGROUND: The molecular classification system categorizes invasive breast carcinomas according to their key driving biomarkers.
  • In the current study, the authors evaluated whether response to neoadjuvant chemotherapy was correlated with the molecular classification groups.
  • METHODS: Using immunohistochemistry, the molecular classification group (luminal-A, luminal-B, HER-2-variant, HER-2-classic, and basal phenotype) was retrospectively determined in 68 breast cancer patients who received neoadjuvant treatment.
  • RESULTS: A total of 28 carcinoma patients (41.2%) achieved a compete pathologic response (CPR), including 2 of 15 patients classified as having luminal-A (13.3%), 4 of 16 patients classified as having luminal-B (25.0%), 10 of 12 patients classified as having HER-2-classic (83.3%), none of the 4 patients classified as having HER-2-variant, and 12 of 21 patients classified as having basal phenotype (57.1%) neoplasms.
  • The CPR rate among patients with the HER-2-classic and basal neoplasms was 67% (22 of 33 neoplasms), compared with 17.1% (6 of 35 neoplasms) in the non-HER-2-classic/basal combined group (P < .001).
  • Eleven carcinomas were initially diagnosed as invasive lobular carcinomas (pleomorphic and classic), 4 of which were luminal-A, 4 of which were luminal-B, 2 of which were HER-2-classic, and 1 of which was basal.
  • On review, only 3 of these 11 cases remained classified as classic lobular carcinoma, all of which were classified as luminal-A, and none of these patients achieved a CPR.
  • CONCLUSIONS: The molecular classification system is useful for identifying carcinoma patients who are most likely and those who are least likely to achieve a CPR.
  • In the current study, all the morphologically classic lobular carcinomas were classified as luminal-A neoplasms, which may explain the low rate of CPR reported.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Breast Neoplasms / classification. Neoadjuvant Therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Carcinoma, Ductal, Breast / classification. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Lobular / classification. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / metabolism. Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Neoplasm Staging. Phenobarbital / metabolism. Prognosis. Receptor, ErbB-2 / metabolism. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Phenobarbital .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17722109.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, ErbB-2; YQE403BP4D / Phenobarbital
  •  go-up   go-down


25. Tubiana-Hulin M, Stevens D, Lasry S, Guinebretière JM, Bouita L, Cohen-Solal C, Cherel P, Rouëssé J: Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. Ann Oncol; 2006 Aug;17(8):1228-33
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution.
  • BACKGROUND: We compared the impact of neoadjuvant chemotherapy on pathologic response and outcome in operable invasive lobular breast carcinoma (ILC) and invasive ductal breast carcinoma (IDC).
  • PATIENTS AND METHODS: We extracted from our database all patients with pure invasive lobular (n=118, 14%) or pure invasive ductal carcinomas (n=742, 86%).
  • Their treatment included neoadjuvant chemotherapy, adapted surgery, radiotherapy and adjuvant hormonal treatment.
  • The outcome at 60 months was significantly better for ILC, but histologic type was not an independent factor for survival in multivariate analysis.
  • CONCLUSIONS: ILC appeared less responsive to chemotherapy but presented a better outcome than IDC.
  • While new information on biological features of ILC is needed, we consider that neoadjuvant endocrine therapy in hormone receptor-positive ILC may be a more adapted approach than neoadjuvant chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16740599.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


26. Peintinger F, Kuerer HM, McGuire SE, Bassett R, Pusztai L, Symmans WF: Residual specimen cellularity after neoadjuvant chemotherapy for breast cancer. Br J Surg; 2008 Apr;95(4):433-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Residual specimen cellularity after neoadjuvant chemotherapy for breast cancer.
  • BACKGROUND: Neoadjuvant chemotherapy for breast cancer reduces tumour cellularity, the percentage of the primary tumour area that is composed of invasive tumour cells.
  • Minimal residual tumour cellularity (5 per cent or less of tumour area composed of invasive tumour cells) may be associated with an increased risk of false-negative intraoperative margins.
  • The aim of this study was to evaluate the incidence of minimal residual tumour cellularity after neoadjuvant chemotherapy and its impact on the frequency of false-negative margins and conversion from breast-conserving surgery to mastectomy.
  • METHODS: The final pathology slides of 510 patients who had surgery after neoadjuvant chemotherapy were reviewed.
  • RESULTS: Of 396 patients with residual invasive breast cancer after neoadjuvant chemotherapy, 100 specimens (25.3 per cent) had minimal residual cellularity; this was more frequent in patients with invasive lobular carcinoma (17.0 versus 5.1 per cent; P < 0.001) or well and moderately differentiated carcinoma (68.0 versus 52.4 per cent; P = 0.007).
  • Among 149 patients who had initial breast-conserving surgery, false-negative intraoperative margin rates were 23 per cent in specimens with minimal and 13.8 per cent in those with higher residual cellularity (P = 0.210).
  • CONCLUSION: Minimal residual cellularity after neoadjuvant chemotherapy occurred in about 25 per cent of specimens, but did not alter the rate of false-negative intraoperative margins.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Mastectomy / methods. Middle Aged. Neoplasm, Residual / pathology. Randomized Controlled Trials as Topic

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 18161887.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  •  go-up   go-down


27. Espié M, Hocini H, Cuvier C, Giacchetti S, Bourstyn E, de Roquancourt A: [Invasive lobular carcinoma of the breast: specific diagnosis and evolution]. Gynecol Obstet Fertil; 2006 Jan;34(1):3-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Invasive lobular carcinoma of the breast: specific diagnosis and evolution].
  • [Transliterated title] Cancer lobulaire infiltrant du sein: particularités diagnostiques et évolutives.
  • Invasive lobular carcinoma accounts for 4 to 10% of breast cancers.
  • Its prognosis is not different from that of infiltrating ductal carcinomas.
  • The choice of therapies depends on the individual characteristics of each patient and of the biological features of each tumour.
  • However, lobular carcinomas seem to be less responsive to chemotherapy.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Lobular / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Invasive lobular carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16406734.001).
  • [ISSN] 1297-9589
  • [Journal-full-title] Gynécologie, obstétrique & fertilité
  • [ISO-abbreviation] Gynecol Obstet Fertil
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


28. Meisamy S, Bolan PJ, Baker EH, Bliss RL, Gulbahce E, Everson LI, Nelson MT, Emory TH, Tuttle TM, Yee D, Garwood M: Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy--a pilot study at 4 T. Radiology; 2004 Nov;233(2):424-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy--a pilot study at 4 T.
  • PURPOSE: To determine if changes in the concentration of choline-containing compounds (tCho) from before primary systemic therapy (PST) to within 24 hours after the first treatment enable prediction of clinical response in patients with locally advanced breast cancer.
  • MATERIALS AND METHODS: Sixteen women with biopsy-confirmed locally advanced breast cancer scheduled to undergo doxorubicin-based PST were recruited.
  • Magnetic resonance (MR) imaging and spectroscopy were performed at 4 T prior to treatment, within 24 hours after the first dose, and after the fourth dose.
  • Of the remaining 13 patients, four had inflammatory breast cancer, six had invasive ductal carcinoma, two had invasive lobular carcinoma, and one had mixed invasive ductal and lobular carcinoma.
  • CONCLUSION: These results suggest that the change in tCho concentration between baseline and 24 hours after the first dose of PST can serve as an indicator for predicting clinical response to doxorubicin-based chemotherapy in locally advanced breast cancer.
  • [MeSH-major] Breast Neoplasms / drug therapy. Magnetic Resonance Spectroscopy. Neoadjuvant Therapy

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15516615.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA92004; United States / NCI NIH HHS / CA / P30 CA77398; United States / NCRR NIH HHS / RR / RR00400; United States / NCRR NIH HHS / RR / RR08079
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] AU0V1LM3JT / Gadolinium
  •  go-up   go-down


29. Londero V, Bazzocchi M, Del Frate C, Puglisi F, Di Loreto C, Francescutti G, Zuiani C: Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol; 2004 Aug;14(8):1371-9
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy.
  • The accuracy of mammography, sonography and magnetic resonance imaging (MRI) in identifying residual disease after neoadjuvant chemotherapy is evaluated and imaging findings are correlated with pathologic findings.
  • Fifteen patients enrolled in an experimental protocol of preoperative neoadjuvant chemotherapy underwent clinical examination, mammography, sonography and dynamic MRI, performed in this order, before and respectively after 2 and 4 cycles of neoadjuvant chemotherapy.
  • MRI resulted in two false-negative results because of the presence of microfoci of in situ ductal carcinoma (DCIS) and invasive lobular carcinoma (LCI).
  • MRI assesses response to neoadjuvant chemotherapy better than traditional methods of physical examination and mammography.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Carcinoma, Lobular / diagnosis. Magnetic Resonance Imaging / methods. Neoadjuvant Therapy. Neoplasm, Residual / diagnosis. Ultrasonography, Mammary / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Jan;17(1):110-9 [10458224.001]
  • [Cites] Radiology. 1995 Dec;197(3):743-7 [7480749.001]
  • [Cites] AJR Am J Roentgenol. 1999 Oct;173(4):911-7 [10511147.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Hong Kong Med J. 2000 Sep;6(3):265-8 [11025844.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(5):949-60 [1639655.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):537-40 [7884412.001]
  • [Cites] Br J Radiol. 1997 May;70(833):452-8 [9227225.001]
  • [Cites] Cancer. 1994 Jul 1;74(1 Suppl):416-23 [8004615.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2672-85 [9704717.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):547-52 [7884414.001]
  • [Cites] Clin Radiol. 1993 May;47(5):339-44 [8508597.001]
  • [Cites] Radiology. 1993 May;187(2):493-501 [8475297.001]
  • [Cites] Radiology. 1999 Dec;213(3):881-8 [10580970.001]
  • [Cites] AJR Am J Roentgenol. 1997 Aug;169(2):417-24 [9242745.001]
  • [Cites] Cancer. 1996 Jul 1;78(1):91-100 [8646731.001]
  • [Cites] Radiology. 1996 Feb;198(2):333-40 [8596827.001]
  • [Cites] J Comput Assist Tomogr. 1997 Sep-Oct;21(5):773-9 [9294574.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2483-93 [9215816.001]
  • [Cites] Radiology. 1996 Feb;198(2):327-32 [8596826.001]
  • [Cites] Radiology. 1994 Jun;191(3):633-8 [8184039.001]
  • [Cites] Radiology. 1989 Apr;171(1):95-103 [2648479.001]
  • [Cites] Eur Radiol. 2002 Jul;12(7):1711-9 [12111062.001]
  • [Cites] J Cancer Educ. 2002 Fall;17(3):138-41 [12243218.001]
  • [Cites] Radiology. 1989 Mar;170(3 Pt 1):681-6 [2916021.001]
  • [Cites] Radiol Med. 1998 May;95(5):449-55 [9687919.001]
  • (PMID = 14986052.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


30. Wenzel C, Bartsch R, Hussian D, Pluschnig U, Altorjai G, Zielinski CC, Lang A, Haid A, Jakesz R, Gnant M, Steger GG: Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF. Breast Cancer Res Treat; 2007 Jul;104(1):109-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF.
  • PURPOSE: Preoperative chemotherapy in patients with primary breast cancer treated with anthracyclines and taxanes results in high response rates, allowing breast conserving surgery (BCS) in patients primarily not suitable for this procedure.
  • We questioned the impact of histologic type invasive ductal carcinoma (IDC) versus invasive lobular carcinoma (ILC) on response to primary chemotherapy.
  • PATIENTS AND METHODS: 161 patients with breast cancer received preoperative chemotherapy consisted of epidoxorubicin 75 mg/m(2) and docetaxel 75 mg/m(2) administered in combination with granulocyte-colony stimulating factor (G-CSF) on days 3-10 (ED + G).
  • Pathological complete response (pCR), biological markers and type of surgery as well as progression free and overall survival were compared between IDC and ILC.
  • Patients with ILC were less likely to have a pCR (3% vs. 20%, P < 0.009) and breast conserving surgeries (51% vs. 79%, P < 0.001).
  • Patients with ILC tended to have longer time to progression (TTP) (42 months vs. 26 months) and overall survival (69 months vs. 65 months).
  • CONCLUSIONS: Our results indicate that patients with ILC achieved a lower pCR rate and ineligibility for BCS to preoperative chemotherapy, but this did not result in a survival disadvantage.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Lobular / drug therapy. Doxorubicin / administration & dosage. Taxoids / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Aged. Austria / epidemiology. Disease-Free Survival. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Middle Aged. Neoadjuvant Therapy. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • Genetic Alliance. consumer health - Invasive lobular carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17061042.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Taxoids; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 15H5577CQD / docetaxel; 80168379AG / Doxorubicin
  •  go-up   go-down


31. Berlière M, Galant C, Marques G, Piette P, Duck L, Fellah L, Donnez J, Machiels JP: LH-RH agonists offer very good protection against the adverse gynaecological effects induced by tamoxifen. Eur J Cancer; 2004 Aug;40(12):1855-61
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Between January 1998 and January 2000, 85 premenopausal breast cancer patients were included in this prospective study.
  • Bone density was also measured at the start of treatment and then after 2, 3 and 4 years.
  • Histology revealed ovarian and endometrial metastases of infiltrating lobular breast carcinoma.
  • Bone density evaluation after 2, 3 and 4 years of treatment showed no significant bone loss.
  • LH-RH agonists offer safe protection against the gynaecological side-effects of tamoxifen in premenopausal breast cancer patients.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Genital Diseases, Female / prevention & control. Gonadotropin-Releasing Hormone / agonists. Tamoxifen / adverse effects
  • [MeSH-minor] Adult. Bone Density / drug effects. Female. Humans. Premenopause. Prospective Studies

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15288287.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen; 33515-09-2 / Gonadotropin-Releasing Hormone
  •  go-up   go-down


32. Rakha EA, El-Sayed ME, Powe DG, Green AR, Habashy H, Grainge MJ, Robertson JF, Blamey R, Gee J, Nicholson RI, Lee AH, Ellis IO: Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. Eur J Cancer; 2008 Jan;44(1):73-83
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes.
  • Invasive lobular carcinoma (ILC) comprises approximately 5-15% of breast cancers and appears to have a distinct biology.
  • It is less common than invasive ductal carcinoma (IDC) and few large studies have addressed its biologic characteristics and behaviour with respect to long-term clinical outcome and response to adjuvant therapy.
  • METHODS: This study is based on a large and well-characterised consecutive series of invasive breast carcinomas with a long-term follow-up (up to 25 years).
  • This series included 415 (8%) patients with pure ILC and 2901 (55.7%) with IDC (not otherwise specified) identified from a consecutive cohort of 5680 breast tumours presented to our Breast Unit that were treated in a similar conventional manner.
  • Clinicopathological, therapy and outcome information as well as data on a large panel of biomarkers were available.
  • Importantly, ILC showed a better response to adjuvant hormonal therapy (HT) with improvement in survival in patients who received HT compared with matched patients with IDC.
  • CONCLUSION: ILC is a distinct entity of breast cancer that responds well to adjuvant HT.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Chemotherapy, Adjuvant. Cohort Studies. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Metastasis / drug therapy. Neoplasm Metastasis / pathology. Neoplasm Staging. Prognosis. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Invasive lobular carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18035533.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor
  •  go-up   go-down


33. Hussien M, Lioe TF, Finnegan J, Spence RA: Surgical treatment for invasive lobular carcinoma of the breast. Breast; 2003 Feb;12(1):23-35
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment for invasive lobular carcinoma of the breast.
  • The management and outcome of 131 women with infiltrating lobular carcinoma treated in the Belfast City Hospital between October 1987 and February 1999 were reviewed.
  • Two patients had primary hormonal treatment and were excluded from the statistical analysis, and 129 patients were followed up.
  • Fifty-four patients (41%) had initial breast conservation surgery, which was followed by re-excision of margins in eight patients (14.8%) and completion total mastectomy in 26 patients (48.1%).
  • The breast conservation surgery group, 28 patients (21.7%), was compared with the total mastectomy group, 101 patients (78.2%), after a median follow-up period of 90 months (range 24-160 months).
  • The type of surgery performed did not affect survival (P=0.42).
  • The total number of patients who developed local recurrence was 17 patients (13.1%, 12 patients in the breast conservation surgery group and five patients in the total mastectomy group, P<0.0001).
  • Kaplan-Meier analysis of local recurrence showed that the type of surgery (P<0.0001), patient age (P=0.02), tumour grade (P=0.002), adjuvant radiotherapy (P=0.013), chemotherapy (P=0.031) and hormonal treatment (P=0.003) significantly affected local recurrence.
  • Cox regression analysis showed that the only factor significantly affecting local recurrence was the type of surgery performed (P=0.02).
  • Patients who underwent mastectomy had less local recurrence than those who had breast conservation surgery.
  • Local recurrence after breast conservation surgery is high, even with clear surgical margins and post-operative radiotherapy.
  • The authors believe that total mastectomy for infiltrating lobular carcinoma is a safer option to control local disease, especially in younger patients and those with high-grade tumours.
  • Overall survival is not affected by the type of surgical treatment.
  • [MeSH-major] Breast Neoplasms / surgery. Carcinoma, Lobular / surgery. Mastectomy, Segmental / methods. Mastectomy, Simple / methods. Neoplasm Recurrence, Local
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Reoperation. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Invasive lobular carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14659352.001).
  • [ISSN] 0960-9776
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


34. Cocquyt V, Van Belle S: Lobular carcinoma in situ and invasive lobular cancer of the breast. Curr Opin Obstet Gynecol; 2005 Feb;17(1):55-60
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lobular carcinoma in situ and invasive lobular cancer of the breast.
  • PURPOSE OF REVIEW: The incidence of lobular carcinoma in situ and invasive lobular carcinoma of the breast is increasing.
  • Recent data suggest that lobular carcinoma in situ is an indolent precursor for breast cancer, rather than a pure risk factor.
  • The risk of contralateral carcinoma and of multifocality of invasive lobular carcinoma is higher than for invasive ductal carcinoma.
  • Conventional mammography or ultrasonography cannot always give useful preoperative information about the extent of lobular cancers.
  • RECENT FINDINGS: The risk of invasive carcinoma after lobular carcinoma in situ is increased.
  • Invasive carcinoma is usually located at the index point of lobular carcinoma in situ and is of lobular histology.
  • Dynamic contrast-enhanced magnetic resonance imaging can be useful in the detection and preoperative staging of invasive lobular carcinoma.
  • The risk of local recurrence is high in patients with invasive lobular carcinoma.
  • Mastectomy and breast reconstruction could be an option in selected patients.
  • The response to preoperative chemotherapy is worse for invasive lobular carcinoma compared with invasive ductal carcinoma, with a greater need for rescue mastectomy.
  • SUMMARY: Lobular carcinoma in situ and invasive lobular carcinoma are different entities from ductal carcinoma in situ and invasive lobular carcinoma.
  • Their biological profile should be studied further in order to make the fine tuning of treatment possible.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Breast Neoplasms / surgery. Carcinoma in Situ / surgery. Carcinoma, Lobular / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Female. Humans. Incidence. Magnetic Resonance Imaging. Mastectomy, Radical. Mastectomy, Segmental. Neoplasm Invasiveness. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / etiology. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Preoperative Care. Prognosis. Risk Factors. Sentinel Lymph Node Biopsy. Survival Rate

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Invasive lobular carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15711412.001).
  • [ISSN] 1040-872X
  • [Journal-full-title] Current opinion in obstetrics & gynecology
  • [ISO-abbreviation] Curr. Opin. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 38
  •  go-up   go-down


35. Chen P, Hu WM, Wang PH, Suen JH: Recurrent breast cancer presents as a single solid ovarian mass and ascites. Taiwan J Obstet Gynecol; 2006 Dec;45(4):356-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent breast cancer presents as a single solid ovarian mass and ascites.
  • However, aside from the primary origin, a metastatic lesion should be considered, since the ovary is frequently metastasized from cancers of other organs, such as the genital tract, gastrointestinal tract, and breast.
  • CASE REPORT: A 47-year-old woman with a history of right breast infiltrating lobular carcinoma, T3N0M0, grade 3, was treated with modified radical mastectomy and axillary lymph-node dissection in July 2001.
  • Therefore, she underwent palliative radiotherapy and various kinds of chemotherapy.
  • However, metastatic carcinoma of the ovary of breast origin was finally diagnosed.
  • [MeSH-major] Ascites / etiology. Breast Neoplasms / pathology. Carcinoma / secondary. Ovarian Neoplasms / secondary

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175500.001).
  • [ISSN] 1875-6263
  • [Journal-full-title] Taiwanese journal of obstetrics & gynecology
  • [ISO-abbreviation] Taiwan J Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


36. Santiago RJ, Harris EE, Qin L, Hwang WT, Solin LJ: Similar long-term results of breast-conservation treatment for Stage I and II invasive lobular carcinoma compared with invasive ductal carcinoma of the breast: The University of Pennsylvania experience. Cancer; 2005 Jun 15;103(12):2447-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Similar long-term results of breast-conservation treatment for Stage I and II invasive lobular carcinoma compared with invasive ductal carcinoma of the breast: The University of Pennsylvania experience.
  • BACKGROUND: The objective of the current study was to determine the long-term results of breast-conservation treatment in women with early-stage, invasive lobular carcinoma of the breast.
  • METHODS: Between 1977 and 1995, 1093 women with Stage I and II invasive ductal carcinoma of the breast and 55 women with invasive lobular carcinoma of the breast underwent lumpectomy, axillary lymph node dissection, and radiation treatment.
  • Overall, 49% of the women received adjuvant systemic therapy (chemotherapy and/or hormones).
  • RESULTS: The median age was 52 years for patients in the invasive ductal group and 54 years for patients in the invasive lobular group.
  • The median follow-up was 8.7 years and 10.2 years for patients in the invasive ductal and invasive lobular groups, respectively.
  • A comparison of patients who had invasive lobular carcinoma with patients who had invasive ductal carcinoma showed no difference in the 10-year actuarial rates of overall survival (85% vs. 79%, respectively; P = 0.73), cause-specific survival (93% vs. 84%, respectively; P = 0.85), or freedom from distant metastases (81% vs. 80%, respectively; P = 0.76).
  • The 10-year rates of local failure were 18% for patients with invasive lobular carcinoma and 12% for patients with invasive ductal carcinoma (P = 0.24), and the 10-year rates of contralateral breast carcinoma development for the 2 groups were 12% and 8%, respectively (P = 0.40).
  • CONCLUSIONS: Breast-conservation treatment yielded similar long-term results for women with early-stage, invasive lobular carcinoma and women with the more prevalent invasive ductal carcinoma.
  • [MeSH-major] Breast Neoplasms / therapy. Carcinoma, Ductal, Breast / therapy. Carcinoma, Lobular / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Lymph Node Excision. Mastectomy, Segmental. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Radiotherapy, Adjuvant. Survival Rate. Time Factors

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • Genetic Alliance. consumer health - Invasive lobular carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 15887223.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


37. Colleoni M, Viale G, Goldhirsch A: Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant setting. Breast; 2009 Oct;18 Suppl 3:S137-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant setting.
  • AIMS: Recommended principles for the choice of therapies in operable breast cancer include the recognition of diverse subtypes of breast cancer and, based on genetic signature and immunohistochemistry, the identification of targets and related factors predictive of response.
  • METHODS AND RESULTS: Experimental and clinical studies have shown that the degree of expression of estrogen receptor (ER) and progesterone receptor (PgR) of the primary tumor defines distinct biological entities that require a differentiated approach to neoadjuvant treatment and clinical trial investigation.
  • In particular, tumors that express high levels of both steroid hormone receptors in a majority of cells derive no or low benefit from preoperative chemotherapy, while the absence of expression of ER and PgR was significantly correlated with the probability of pathologic complete remission (pCR).
  • It was also demonstrated that the pCR rate to primary chemotherapy is significantly lower in invasive lobular carcinoma, frequently characterized by a high expression of steroid hormone receptors, if compared with the ductal histotype.
  • Direct or indirect measures of high cell proliferation (elevated Ki-67 labeling index and high grade) identified patients with tumors responsive to chemotherapy in the preoperative setting.
  • These factors might therefore assist in the identification of patients who might benefit from chemotherapy, in particular those patients with endocrine responsiveness.
  • HER2 overexpression or amplification represents a target for neoadjuvant treatment with the humanised monoclonal antibody against its extracellular domain, but is also a factor predictive of response to neoadjuvant systemic therapies.
  • A statistically significant positive correlation between HER2 positivity and pCR rate in patients treated with neoadjuvant chemotherapy was recently shown.
  • CONCLUSIONS: Results from studies in the neoadjuvant setting indicate that the use of factors predictive of response may permit a more effective application of therapies identifying patients likely to obtain substantial benefit from treatment.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / drug therapy. Neoadjuvant Therapy
  • [MeSH-minor] Antineoplastic Agents, Hormonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Female. Humans. Predictive Value of Tests. Prognosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19914533.001).
  • [ISSN] 1532-3080
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor
  • [Number-of-references] 44
  •  go-up   go-down


38. Ustaalioglu BB, Bilici A, Seker M, Salman T, Gumus M, Barisik NO, Salepci T, Yaylaci M: Metastasis of lobular breast carcinoma to the uterus in a patient under anastrozole therapy. Onkologie; 2009 Jul;32(7):424-6
Hazardous Substances Data Bank. ANASTROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of lobular breast carcinoma to the uterus in a patient under anastrozole therapy.
  • Lobular carcinoma is the most common type of breast cancer that metastasizes to the uterus.
  • CASE REPORT: We report on a 56-year-old woman who 3 years previously was diagnosed with invasive lobular carcinoma of the breast and was treated with surgery followed by chemotherapy and radiotherapy.
  • While the patient was on adjuvant anastrozole therapy for 2 years, she complained of vaginal bleeding.
  • Histopathologic examination of the specimens revealed carcinoma infiltration of the myometrium, endometrium, cervix, uterine tube, and left ovary.
  • Immunohistochemical staining of tumoral cells with pancytokeratin and gross cystic disease fluid protein (GCDFP-15) proved the diagnosis of metastatic lobular breast carcinoma to the uterus.
  • CONCLUSION: To our knowledge, this is the second case of lobular breast carcinoma metastasized to the uterus under anastrozole therapy.
  • In women with lobular breast cancer under adjuvant anastrozole therapy, who present with vaginal bleeding, uterine metastasis of lobular carcinoma should be considered in the differential diagnosis.
  • [MeSH-major] Breast Neoplasms / complications. Breast Neoplasms / drug therapy. Carcinoma, Lobular / chemically induced. Carcinoma, Lobular / secondary. Nitriles / adverse effects. Nitriles / therapeutic use. Triazoles / adverse effects. Triazoles / therapeutic use. Uterine Neoplasms / chemically induced. Uterine Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Agents, Hormonal / adverse effects. Antineoplastic Agents, Hormonal / therapeutic use. Diagnosis, Differential. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19556822.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Nitriles; 0 / Triazoles; 2Z07MYW1AZ / anastrozole
  •  go-up   go-down


39. Shin SJ, DeLellis RA, Ying L, Rosen PP: Small cell carcinoma of the breast: a clinicopathologic and immunohistochemical study of nine patients. Am J Surg Pathol; 2000 Sep;24(9):1231-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell carcinoma of the breast: a clinicopathologic and immunohistochemical study of nine patients.
  • Small cell carcinoma of the breast is an uncommon neoplasm that has been reported rarely in the literature.
  • Nine examples of mammary small cell carcinoma were retrieved from the authors' consultation files and reviewed.
  • Two patients had a previous history of cutaneous malignant melanoma and one had prior lobular carcinoma in situ and atypical duct hyperplasia in the same breast as the small cell carcinoma.
  • Eight patients presented with a mass in the breast; one patient had an axillary tumor.
  • Histologically, the nine tumors had characteristics of small cell carcinoma with high mitotic activity and necrosis.
  • In one instance, this consisted of small cell carcinoma merging with invasive lobular carcinoma.
  • In three cases, small cell carcinoma was present together with invasive, poorly differentiated duct carcinoma; invasive carcinoma with "lobular and gland-forming elements"; and focal squamous differentiation, respectively.
  • An in situ component was seen in seven tumors; five were of the small cell type in ducts and two were of the ductal type with high nuclear grade.
  • Eight underwent an axillary dissection that revealed metastatic carcinoma in four patients.
  • Seven patients received adjuvant chemotherapy and four patients received radiation.
  • Two patients also received tamoxifen treatment.
  • Metastases developed in two patients (22%) with a follow-up period of 11 and 32 months.
  • All patients were alive at last follow up 3 to 35 months after treatment.
  • When compared with published reports of mammary small cell carcinoma, our results show that the prognosis in these patients may not be as poor as previously suggested.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Small Cell / pathology
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Immunohistochemistry. Keratins / metabolism. Middle Aged. Receptors, Estrogen / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2001 Jun;25(6):831-2 [11395567.001]
  • (PMID = 10976697.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 68238-35-7 / Keratins
  •  go-up   go-down


40. Niu Y, Fu XL, Yu Y, Wang PP, Cao XC: Intra-operative frozen section diagnosis of breast lesions: a retrospective analysis of 13,243 Chinese patients. Chin Med J (Engl); 2007 Apr 20;120(8):630-5
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-operative frozen section diagnosis of breast lesions: a retrospective analysis of 13,243 Chinese patients.
  • BACKGROUND: Although cytological methods for breast oncology have been used in recent decades, intra-operative frozen section has been playing a vital role in making therapeutic decisions.
  • We analyzed a large series of frozen section diagnoses for Chinese cases of breast lesion within the last 15 years.
  • The experience was expected to increase the diagnostic accuracy of cases with breast lesions.
  • METHODS: The data from consecutive 13243 cases of breast lesions diagnosed with intra-operative frozen sections between 1988 to 2002 were compared with paraffin sections in a case by case manner.
  • Six types (false invasion, peri-papilloma, adenoma of nipple duct, florid adenosis, sclerosing adenosis, and granulose cell tumor) of lesions may lead to false positive, and four types (morphological changes responding chemotherapy, well differentiated papillary carcinoma, invasive lobular carcinoma, and tubular carcinoma) to a false negative.
  • Gross and microscopic findings may be inconsistent in two types of lesions (radial scar and florid adenosis) microscopic and clinical findings in three types (ganulomatous mastitis mammary, duct ectasia, and fat necrosis), and three types (abundant fat or sclerous tissues; borderline lesions and changes of post-chemotherapy) were likely wrongly classified.
  • CONCLUSIONS: Intra-operative frozen section can accurately identify breast lesions in many instances, leading to fewer errors on account of more diagnostic experience and understanding of diagnostic limitations.
  • [MeSH-major] Breast Diseases / diagnosis. Breast Neoplasms / diagnosis. Frozen Sections / methods
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Biopsy / methods. Breast / pathology. Child. China. Female. Humans. Intraoperative Care / methods. Male. Middle Aged. Paraffin Embedding / methods. Reproducibility of Results. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17517175.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


41. Brankovic-Magic MV, Jankovic RN, Dobricic JD, Borojevic ND, Magic ZM, Radulovic SS: TP53 mutations in breast cancer: association with ductal histology and early relapse of disease. Int J Biol Markers; 2008 Jul-Sep;23(3):147-53
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TP53 mutations in breast cancer: association with ductal histology and early relapse of disease.
  • PURPOSE: This study aimed to investigate the incidence of core domain TP53 mutations in Serbian breast cancer patients in view of their possible correlation with prognostic parameters, tumor characteristics and clinical disease course.
  • METHODS: 145 breast cancer patients were included.
  • After surgery, node-positive patients underwent adjuvant chemotherapy, mostly CMF.
  • 26/31 TP53 mutations were found in patients with invasive ductal carcinoma and only 2 in patients with invasive lobular carcinoma.
  • The significance of the predominant distribution of TP53 mutations in tumors with a ductal histology for the aggressive behavior of these tumors has yet to be proved, since the favorable biological features of tumors with a lobular histology do not result in a better prognosis.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. Genes, p53. Mutation. Tumor Suppressor Protein p53 / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18949740.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Steroid; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


42. Akcali Z, Sakalli H, Ozyilkan O, Demirhan B, Haberal M: Prognostically favorable abdominal breast cancer metastases with stomach involvement. Onkologie; 2005 May;28(5):270-2
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostically favorable abdominal breast cancer metastases with stomach involvement.
  • BACKGROUND: Abdominal metastases with stomach involvement are rare in breast cancer.
  • The median disease free interval from the time of breast cancer diagnosis to gastric metastasis is usually very long.
  • Treatment is generally palliative, and expected survival time is less than 1 year.
  • CASE REPORT: A 59-year-old woman with breast cancer developed diffuse abdominal metastases involving stomach, abdominal lymph nodes, and omentum 9 years after she underwent mastectomy and adjuvant chemotherapy.
  • The histopathologic diagnosis found by stomach specimen examination was invasive lobular carcinoma, and the cells expressed high levels of estrogen and progesterone receptors.
  • The abdominal metastases were treated with surgery, postoperative chemotherapy, and further hormonal therapy.
  • CONCLUSION: Once the definitive diagnosis of breast cancer metastases to the abdomen including the stomach is established, treatment that targets systemic breast cancer must be initiated.
  • Our patient's extended survival time suggests that surgical treatment could be considered for selected patients.
  • [MeSH-major] Abdominal Neoplasms / secondary. Breast Neoplasms / surgery. Carcinoma, Lobular / secondary. Stomach Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Gastrectomy. Humans. Mastectomy. Middle Aged. Neoplasm Invasiveness. Reoperation. Stomach / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15867484.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


43. Gundry KR: The application of breast MRI in staging and screening for breast cancer. Oncology (Williston Park); 2005 Feb;19(2):159-69; discussion 170, 173-4, 177
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The application of breast MRI in staging and screening for breast cancer.
  • Contrast-enhanced breast magnetic resonance imaging (MRI) is a relatively new but increasingly used modality for the detection of breast cancer.
  • MRI has demonstrated utility in identifying additional tumor foci and extent of disease in patients with known breast cancer.
  • This is especially useful with invasive lobular carcinoma, which is difficult to evaluate on mammography.
  • MRI has been found to identify the primary tumor in 70% to 86% of cases of occult breast cancer.
  • Contrast-enhanced breast MRI has shown some usefulness in the detection of residual cancer following surgery but is limited by postoperative changes.
  • In patients who have undergone neoadjuvant chemotherapy, breast MRI is most accurate in those patients in whom there is little or no response to chemotherapy.
  • The use of contrast-enhanced breast MRlfor breast cancer screening is controversial.
  • The limitations of breast MRI include uptake in benign lesions and normal tissue, sensitivity for ductal carcinoma in situ, cost, and availability.
  • This paper will discuss the uses, benefits, and limitations of contrast-enhanced breast MRI in the staging and screening of breast cancer.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Magnetic Resonance Imaging. Mass Screening. Neoplasm Staging / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15770888.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 58
  •  go-up   go-down


44. Hayashi K, Sengoku N, Kosaka Y, Enomoto T, Kajita S, Kondo Y, Kuranami M, Watanabe M: [A long-term survival case of progressive breast cancer detected in gastric metastasis]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2756-9
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A long-term survival case of progressive breast cancer detected in gastric metastasis].
  • A 51-year-old postmenopausal woman was diagnosed as having adenocarcinoma (gastric cancer type 4) from gastric biopsy by upper endoscopy.
  • Meanwhile, a breast CT suggested tumor in her left breast and was diagnosed as an invasive lobular carcinoma based on a core needle biopsy.
  • After gastric biopsy, tissues are stained by ER and PgR in immunohistochemistry.
  • The diagnosis was modified from gastric cancer to T2N1M1, stage IV left breast cancer, accompanied by a treatment.
  • Chemotherapy with EC 6 course consisted of a weekly PTX 4 course (epirubicin, cyclophosphamide-weekly paclitaxel) was performed.
  • After the chemotherapy, breast mass, ascites and tumor marker were dramatically improved.
  • Then hormonal therapy was administered.
  • Metastatic gastric tumors simulating type 4 advanced gastric cancer (MGTS type 4) and invasive lobular carcinoma are known to have an unfavorable prognosis.
  • There is no doubt, however, that the multidisciplinary treatments have brought a satisfaction to her and family.
  • We should keep in mind a possibility of gastric metastasis of breast cancer, when consulting a female patient with gastric cancer type 4.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / pathology. Stomach Neoplasms / secondary

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224703.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


45. Ohri A, Jetly D, Shukla K, Bansal R: Cytological grading of breast neoplasia and its correlation with histological grading. Indian J Pathol Microbiol; 2006 Apr;49(2):208-13
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytological grading of breast neoplasia and its correlation with histological grading.
  • Cytological grading of breast cancer is not well established despite histological grading having gained a strong foothold.
  • In our study we have analyzed 50 cases of breast carcinoma which included invasive ductal carcinoma, invasive lobular carcinoma, mucinous carcinoma, stromal sarcoma, apocrine carcinoma, papillary carcinoma.
  • Simplified Black grading system has been recommended for cytological grading of breast neoplasia because of its lucidity and its reproducibility.
  • Cytological grading of breast neoplasia is important for neo adjuvant chemotherapy and also for predicting the prognosis of the patient on FNAC alone.
  • [MeSH-major] Breast Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16933716.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] India
  •  go-up   go-down


46. Luczyńska E, Pawlik T, Chwalibóg A, Anioł J, Ryś J: Metastatic Breast Cancer to the Bladder case report and review of literature. J Radiol Case Rep; 2010;4(5):19-26

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic Breast Cancer to the Bladder case report and review of literature.
  • The main cause of mortality among patients with breast cancer is the metastatic spread of the primary tumour.
  • The urinary bladder is considered as an unusual site for breast cancer metastasis.
  • A patient has presented with right breast tumour and qualified for surgical treatment.
  • After removal of the mass, an intra-operative and final pathology evaluation indicated breast invasive lobular carcinoma.
  • Adjuvant chemotherapy was given.
  • A transurethral resection of bladder was performed, reaffirming a neoplastic mass, with histological assessment revealing invasive breast carcinoma.
  • Palliative chemotherapy was given and another follow-up ultrasound scans were unremarkable.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22470730.001).
  • [ISSN] 1943-0922
  • [Journal-full-title] Journal of radiology case reports
  • [ISO-abbreviation] J Radiol Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3303405
  • [Keywords] NOTNLM ; Breast cancer / breast invasive lobular carcinoma / recurrent lesion / transurethral resection / urinary bladder metastasis
  •  go-up   go-down


47. Tse GM, Chaiwun B, Wong KT, Yeung DK, Pang AL, Tang AP, Cheung HS: Magnetic resonance imaging of breast lesions--a pathologic correlation. Breast Cancer Res Treat; 2007 May;103(1):1-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging of breast lesions--a pathologic correlation.
  • Magnetic resonance imaging of the breast is useful in assessing breast lesions.
  • These correlate with the pathological features of breast tumor, characterized by rapid growth rate, large size, and infiltrative growth pattern, invasion into stroma resulting in desmoplasia, and hence irregular outline and margin.
  • The detection and estimation of tumor extent of invasive lobular carcinoma is problematic, even with magnetic resonance imaging, which is considered the most sensitivity.
  • Estimation of tumor extent after neoadjuvant chemotherapy is also essential but problematic by imaging, as the shrunken tumor becomes fibrotic, with stromal hyalinization, diminished microvasculature and tumor break up causing size underestimation.
  • Non-enhancement of breast tumors occurs in about 8% of cases correlates with diffuse growth pattern, particularly of infiltrative lobular carcinoma.
  • The observation of disproportionately high non-enhancing ductal carcinoma in situ remains an enigma.
  • [MeSH-major] Breast Neoplasms / pathology. Magnetic Resonance Imaging

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17033923.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 69
  •  go-up   go-down


48. Biglia N, Mariani L, Sgro L, Mininanni P, Moggio G, Sismondi P: Increased incidence of lobular breast cancer in women treated with hormone replacement therapy: implications for diagnosis, surgical and medical treatment. Endocr Relat Cancer; 2007 Sep;14(3):549-67
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased incidence of lobular breast cancer in women treated with hormone replacement therapy: implications for diagnosis, surgical and medical treatment.
  • A growing body of evidence support the association between the use of hormone replacement therapy (HRT) and a higher risk of both invasive lobular carcinoma (ILC) and invasive ductal-lobular mixed carcinoma (IDLC).
  • Overall biological and clinical features of ILC entail a more cautious diagnostic and therapeutic approach as compared with invasive ductal carcinoma (IDC).
  • Mammography and ultrasound show, therefore, significant limitations, while the higher sensitivity of magnetic resonance imaging in the detection of multifocal and/or multicentric lesions seems to improve the accuracy of preoperative staging of ILCs.
  • Early diagnosis is even more challenging because the difficult in the localization and the sparse cellularity of lobular tumours may determine a false negative core biopsy.
  • Since lobular histology is associated with a higher risk of positive margins, mastectomy is often preferred to breast conservative surgery.
  • Moreover, only few patients with ILC achieve a pathologic response to preoperative chemotherapy and, therefore, in most patients mastectomy can be regarded as the safer surgical treatment.
  • [MeSH-major] Breast Neoplasms / chemically induced. Breast Neoplasms / epidemiology. Carcinoma, Lobular / chemically induced. Carcinoma, Lobular / epidemiology. Estrogen Replacement Therapy / adverse effects
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Fine-Needle. Combined Modality Therapy. Feasibility Studies. Female. Humans. Incidence. Intraoperative Period. Magnetic Resonance Imaging. Mammography. Mastectomy, Segmental. Mastectomy, Simple. Neoplasm Invasiveness / diagnosis. Prognosis. Risk Assessment. Sentinel Lymph Node Biopsy. Ultrasonography, Mammary

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17914088.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 122
  •  go-up   go-down


49. Kinkel K, Hylton NM: Challenges to interpretation of breast MRI. J Magn Reson Imaging; 2001 Jun;13(6):821-9
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Challenges to interpretation of breast MRI.
  • This review describes the current knowledge and challenges of lesion interpretation with MRI of the breast according to different image interpretation strategies.
  • The impacts of the menstrual cycle, prior surgery, radiation therapy, and chemotherapy are summarized.
  • Particular enhancement features of ductal carcinoma in situ (DCIS) or invasive lobular carcinoma are described.
  • Finally, an adequate diagnosis at MRI of the breast should take into account the results of the patient's history, physical examination, and all imaging tests performed before MRI. J. Magn. Reson.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / diagnosis. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Carcinoma, Lobular / diagnosis. Magnetic Resonance Imaging. Neoplasm Recurrence, Local / diagnosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11382939.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 46
  •  go-up   go-down


50. Farese SA, Aebi S: Infiltrating lobular carcinoma of the breast: systemic treatment. Breast Dis; 2008-2009;30:45-52
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infiltrating lobular carcinoma of the breast: systemic treatment.
  • Invasive lobular carcinoma (ILC) is the second most common type of breast cancer after invasive ductal carcinoma (IDC).
  • We have reviewed selected literature on preoperative (neoadjuvant) and adjuvant systemic therapy of breast cancer focusing on the differential therapy of ILC.
  • Despite the importance of this type of breast cancer, information about its specific treatment is sparse, in particular with regard to adjuvant systemic chemotherapy.
  • ILC has significantly lower rates of response to neoadjuvant chemotherapy compared with IDC; however, the low chemosensitivity seems not to result in a survival disadvantage.
  • Adjuvant hormonal therapy studies do not distinguish between ILC and IDC.
  • Thus, recommendations about endocrine therapies are made using the same criteria as for IDC.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Lobular / drug therapy
  • [MeSH-minor] Antineoplastic Agents, Hormonal / therapeutic use. Aromatase Inhibitors / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Neoadjuvant Therapy

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19850995.001).
  • [ISSN] 1558-1551
  • [Journal-full-title] Breast disease
  • [ISO-abbreviation] Breast Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal; 0 / Aromatase Inhibitors
  •  go-up   go-down


51. Solin LJ, Fourquet A, Vicini FA, Haffty B, Taylor M, McCormick B, McNeese M, Pierce LJ, Landmann C, Olivotto IA, Borger J, de La Rochefordiere A, Schultz DJ: Salvage treatment for local recurrence after breast-conserving surgery and radiation as initial treatment for mammographically detected ductal carcinoma in situ of the breast. Cancer; 2001 Mar 15;91(6):1090-7
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage treatment for local recurrence after breast-conserving surgery and radiation as initial treatment for mammographically detected ductal carcinoma in situ of the breast.
  • BACKGROUND: The purpose of the current study is to evaluate the outcome of salvage treatment for local recurrence after breast-conserving surgery and radiation as initial treatment for mammographically detected ductal carcinoma in situ (DCIS; intraductal carcinoma) of the breast.
  • METHODS: An analysis was performed of 42 patients with local only first failure (n = 41) or local-regional only first failure (n = 1) after breast-conserving surgery and radiation treatment had been given for DCIS of the breast.
  • Surgical treatment at the time of local recurrence included mastectomy (n = 37; 88%) or excision (n = 5; 12%).
  • Adjuvant systemic therapy at the time of local recurrence was chemotherapy (n = 3; 7%), tamoxifen (n = 8; 19%), both (n = 1; 2%), none (n = 29; 69%), or unknown (n = 1; 2%).
  • The median interval from the time of initial treatment to local recurrence was 4.8 years (range = 1.0-15.2 yrs).
  • The median follow-up after salvage treatment was 4.5 years (range = 0.2-12.8 yrs).
  • RESULTS: At the time of the local recurrence, 22 patients (52%) had invasive ductal carcinoma, 18 patients (43%) had DCIS, 1 patient (2%) had invasive lobular carcinoma, and 1 patient (2%) had angiosarcoma.
  • After salvage treatment, the rate of overall survival and the rate of cause specific survival for all 42 patients were 92% at both 5- and 8-years after treatment.
  • Favorable prognostic factors after salvage treatment were DCIS as the histology of the local recurrence and mammography only as the method of detection of the local recurrence.
  • CONCLUSIONS: The results of salvage treatment in the current study demonstrated that local recurrences were salvaged with high rates of survival and freedom from distant metastases.
  • These results support the use of breast-conserving surgery and radiation for initial management of DCIS of the breast.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / surgery. Carcinoma, Intraductal, Noninfiltrating / drug therapy. Carcinoma, Intraductal, Noninfiltrating / surgery. Mastectomy, Segmental. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Hormonal / administration & dosage. Databases, Factual. Female. Humans. Mammography. Mastectomy. Middle Aged. Retrospective Studies. Salvage Therapy. Survival Analysis. Tamoxifen / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11267953.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


52. Teller P, Jefford VJ, Gabram SG, Newell M, Carlson GW: The utility of breast MRI in the management of breast cancer. Breast J; 2010 Jul-Aug;16(4):394-403
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The utility of breast MRI in the management of breast cancer.
  • Breast magnetic resonance imaging (MRI) is increasingly used in the evaluation of breast cancer.
  • A retrospective review was performed for 114 breast cancer patients who had breast MRI as part of their diagnostic evaluation.
  • Clinical information, mammograms, breast ultrasounds and MRI scans were reviewed to determine whether the MRI findings led to a change in patient management.
  • Outcomes as the result of breast MRI were stratified as favorable and unfavorable.
  • The indications for breast MRI included: high risk screening (n = 3), diagnostic evaluation of disease after neo-adjuvant chemotherapy (n = 24) or prior to re-excision (n = 8), extent of in situ ductal, infiltrating ductal or infiltrating lobular disease histology (DCIS n = 3, IDC n = 24, ILC n = 17), identification of unknown primary (n = 2), assessment of contralateral breast (n = 4), recurrence surveillance (n = 5), and other (n = 5).
  • Diagnostic evaluation of the breast by MRI alters patient management in 30% of cases depending upon the indications.
  • Evaluation of the breast by MRI alters the clinical management of nearly one-third of patients.
  • Patients undergoing evaluation for contralateral disease, invasive lobular carcinoma and assessment of chemotherapeutic response may derive a more meaningful benefit from MRI.
  • [MeSH-major] Breast Neoplasms / surgery. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Early Detection of Cancer. Female. Humans. Mammography. Middle Aged. Neoplasm Staging. Retrospective Studies

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20545940.001).
  • [ISSN] 1524-4741
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Yoney A, Kucuk A, Unsal M: Male breast cancer: a retrospective analysis. Cancer Radiother; 2009 Apr;13(2):103-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Male breast cancer: a retrospective analysis.
  • BACKGROUND: To evaluate our results in the treatment of male breast cancer patients with respect to local control (LC), overall survival (OS) and possible prognosis factors for survival.
  • PATIENTS AND METHODS: Thirty-nine patients with male breast cancer have been retrospectively studied with the trial aim to evaluate the results of our practice.
  • Among them, 94.8% had invasive ductal carcinoma (IDC), 2.6% invasive papillary carcinoma (IPC) and 2.6% invasive lobular carcinoma (ILC) and the distribution according to stage was found to be 12.8, 46.2, 30.7 and 10.3% in Stages I, II, III and IV, respectively.
  • Among the patients, 7.7% received radiotherapy (RT) and hormonotherapy (HT), 22.8% received chemotherapy (CT), 61.8% received chemoradiotherapy (CRT) and HT and 7.7% received HT in addition to surgery.
  • In our series, univariate analysis for OS demonstrated statistical significance for lymph node metastases (p=0.00001), stage (p=0.0098) and age (p=0.03); while RT in the treatment modality (p=0.6849), and tumor size (p=0.4439) demonstrated no significance.
  • CONCLUSION: Postoperative radiotherapy was important in the management of male breast cancer to improve LC resulting in one local failure, but did not improve OS and DFS in our analysis.
  • [MeSH-major] Breast Neoplasms, Male / mortality. Breast Neoplasms, Male / therapy
  • [MeSH-minor] Adult. Age Factors. Aged. Carcinoma, Ductal, Breast / mortality. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / therapy. Carcinoma, Lobular / mortality. Carcinoma, Lobular / pathology. Carcinoma, Lobular / therapy. Carcinoma, Papillary / mortality. Carcinoma, Papillary / pathology. Carcinoma, Papillary / therapy. Disease-Free Survival. Humans. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Retrospective Studies

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Breast Cancer, Male.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19250851.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


54. Zhou M, Johnson N, Gruner S, Ecklund GW, Meunier P, Bryn S, Glissmeyer M, Steinbock K: Clinical utility of breast-specific gamma imaging for evaluating disease extent in the newly diagnosed breast cancer patient. Am J Surg; 2009 Feb;197(2):159-63
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical utility of breast-specific gamma imaging for evaluating disease extent in the newly diagnosed breast cancer patient.
  • BACKGROUND: Breast-specific gamma imaging (BSGI) is a functional imaging modality that has comparable sensitivity but superior specificity compared with magnetic resonance imaging, yielding fewer false-positive results and thereby improving clinical management of the newly diagnosed breast cancer patient.
  • METHODS: A retrospective review was performed from 2 community-based breast imaging centers of newly diagnosed breast cancer patients in whom BSGI was performed as part of the imaging work-up.
  • RESULTS: A total of 138 patients (69 invasive ductal carcinoma, 20 invasive lobular carcinoma, 32 ductal carcinoma in situ, and 17 mixtures of invasive ductal carcinoma, invasive lobular carcinoma, or ductal carcinoma in situ and other) were reviewed.
  • Twenty-five patients (18.1%) had a positive BSGI study at a site remote from their known cancer or more extensive disease than detected from previous imaging.
  • Fifteen patients (10.9%) were positive for a synchronous or more extensive malignancy in the same or contralateral breast.
  • Findings converted 7 patients to mastectomy, 1 patient to neoadjuvant chemotherapy, and 7 patients were found to have previously undetected contralateral cancer.
  • CONCLUSIONS: BSGI detected additional or more extensive malignancy in the same or contralateral breast in 10.9% of newly diagnosed breast cancer patients.
  • BSGI provides accurate evaluation of remaining breast tissue in newly diagnosed breast cancer patients with few false-positive readings.
  • [MeSH-major] Breast Neoplasms / radionuclide imaging

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19185109.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


55. Piechocki MP: A stable explant culture of HER2/neu invasive carcinoma supported by alpha-Smooth Muscle Actin expressing stromal cells to evaluate therapeutic agents. BMC Cancer; 2008;8:119
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A stable explant culture of HER2/neu invasive carcinoma supported by alpha-Smooth Muscle Actin expressing stromal cells to evaluate therapeutic agents.
  • BACKGROUND: To gain a better understanding of the effects of therapeutic agents on the tumor microenvironment in invasive cancers, we developed a co-culture model from an invasive lobular carcinoma.
  • This co-culture, Mammary Adenocarcinoma Model (MAM-1) maintains a 1:1 ratio of HER2/neu positive tumor cells to alpha-SMA-reactive stromal cells and renews this configuration for over 20 passages in vitro.
  • We developed flow cytometric assays to evaluate the relative responses of the tumor and stroma to the tyrosine kinase inhibitor, Iressa.
  • RESULTS: The MAM-1 gene expression profile contains clusters that represent the ErbB-2 breast cancer signature and stroma-specific clusters associated with invasive breast cancers.
  • Treatment resulted in a selective dose-dependent reduction in phospho-pMEK1/2 and pp44/42MAPK in tumor cells.
  • CONCLUSION: This model demonstrates the specificity of Iressa for HER2/neu expressing tumor cells versus the tumor associated myofibroblasts and is appropriate for delineating effects of therapy on signal transduction in the breast tumor microenvironment and improving strategies that can dually or differentially target the tumor and stromal elements in the microenvironment.
  • [MeSH-major] Actins / metabolism. Cell Culture Techniques. Genes, erbB-2. Mammary Neoplasms, Experimental / drug therapy. Mammary Neoplasms, Experimental / genetics. Muscle, Smooth / cytology. Stromal Cells / metabolism
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Adenocarcinoma / pathology. Animals. Antineoplastic Agents / pharmacokinetics. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / genetics. Carcinoma, Lobular / pathology. Cell Line, Tumor / metabolism. Coculture Techniques. Dose-Response Relationship, Drug. Flow Cytometry. Gene Expression Regulation, Neoplastic / drug effects. Male. Mice. Mice, Transgenic. Models, Biological. Quinazolines / pharmacokinetics


56. Kuo WH, Yen AM, Lee PH, Hou MF, Chen SC, Chen KM, Chen TH, Chang KJ: Incidence and risk factors associated with bilateral breast cancer in area with early age diagnosis but low incidence of primary breast cancer: analysis of 10-year longitudinal cohort in Taiwan. Breast Cancer Res Treat; 2006 Sep;99(2):221-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and risk factors associated with bilateral breast cancer in area with early age diagnosis but low incidence of primary breast cancer: analysis of 10-year longitudinal cohort in Taiwan.
  • This study aims to examine the incidence and risk factors of bilateral breast cancer in area with low incidence rate.
  • A total of 120 and 1902 women with bilateral and unilateral breast cancers were enrolled; various factors, including those concerning their medical history and life style, were extracted.
  • Using Kaplan-Meier method, we calculate the cumulative incidence of contralateral breast cancer.
  • The cumulative incidences of contralateral breast cancer at 1, 3, 5 years after diagnosis of first breast cancer were 1.15, 1.94, and 2.97%, respectively.
  • The statistically significant risk factors included menopause (Hazard Ratio (HR) =1.56, (1.00-2.42)), invasive lobular carcinoma (HR=2.98, (1.35-6.56)), receiving chemotherapy (HR=2.21, (1.43-3.42)) and/or radiotherapy (HR=3.32, (2.19-5.05) and a protective factor was tamoxifen therapy (HR=0.5 (0.34-0.74).
  • Comparing to the existing data on Western countries, we find a higher risk for developing contralateral breast cancer in Taiwan where a low incidence of first breast cancer rate with early age diagnosis is noted.
  • It suggests that first primary breast tumour with early age of onset and lobular carcinoma are found more likely to develop bilateral breast cancers.
  • [MeSH-major] Breast Neoplasms / epidemiology. Carcinoma, Ductal, Breast / epidemiology. Carcinoma, Intraductal, Noninfiltrating / epidemiology. Carcinoma, Lobular / epidemiology
  • [MeSH-minor] Adult. Cohort Studies. Female. Humans. Incidence. Longitudinal Studies. Lymphatic Metastasis / pathology. Menopause. Middle Aged. Risk Factors. Taiwan / epidemiology. Time Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16544057.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


57. Riggins RB, Lan JP, Zhu Y, Klimach U, Zwart A, Cavalli LR, Haddad BR, Chen L, Gong T, Xuan J, Ethier SP, Clarke R: ERRgamma mediates tamoxifen resistance in novel models of invasive lobular breast cancer. Cancer Res; 2008 Nov 01;68(21):8908-17
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ERRgamma mediates tamoxifen resistance in novel models of invasive lobular breast cancer.
  • One-third of all estrogen receptor (ER)-positive breast tumors treated with endocrine therapy fail to respond, and the remainder is likely to relapse in the future.
  • Almost all data on endocrine resistance has been obtained in models of invasive ductal carcinoma (IDC).
  • However, invasive lobular carcinomas (ILC) comprise up to 15% of newly diagnosed invasive breast cancers each year and, whereas the incidence of IDC has remained relatively constant during the last 20 years, the prevalence of ILC continues to increase among postmenopausal women.
  • We report a new model of Tamoxifen (TAM)-resistant invasive lobular breast carcinoma cells that provides novel insights into the molecular mechanisms of endocrine resistance.
  • Knockdown of ERRgamma in SUM44/LCCTam cells by siRNA restores TAM sensitivity, and overexpression of ERRgamma blocks the growth-inhibitory effects of TAM in SUM44 and MDA-MB-134 VI lobular breast cancer cells.
  • [MeSH-major] Antineoplastic Agents, Hormonal / pharmacology. Breast Neoplasms / pathology. Carcinoma, Lobular / pathology. Drug Resistance, Neoplasm. Receptors, Estrogen / physiology. Tamoxifen / analogs & derivatives

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Dec;81(8):1328-34 [10604729.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Natl Cancer Inst. 2000 Dec 6;92(23):1926-34 [11106684.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):278-84 [11196175.001]
  • [Cites] Cochrane Database Syst Rev. 2001;(1):CD000486 [11279694.001]
  • [Cites] J Steroid Biochem Mol Biol. 2001 Jan-Mar;76(1-5):71-84 [11384865.001]
  • [Cites] Mol Cell. 2002 Feb;9(2):303-13 [11864604.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1155-66 [12006532.001]
  • [Cites] Trends Endocrinol Metab. 2002 Jul;13(5):220-5 [12185669.001]
  • [Cites] Biochem J. 2000 Sep 15;350 Pt 3:785-90 [10970793.001]
  • [Cites] Cancer Res. 2008 Jul 1;68(13):5246-56 [18593925.001]
  • [Cites] Clin Cancer Res. 1999 Feb;5(2):251-6 [10037172.001]
  • [Cites] Stat Med. 2002 Nov 30;21(22):3465-74 [12407684.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6510-8 [12438245.001]
  • [Cites] JAMA. 2003 Mar 19;289(11):1421-4 [12636465.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3576-9 [12824369.001]
  • [Cites] J Biol Chem. 2003 Oct 10;278(41):40213-23 [12832416.001]
  • [Cites] Oncogene. 2003 Oct 20;22(47):7316-39 [14576841.001]
  • [Cites] J Mol Endocrinol. 2003 Dec;31(3):349-57 [14664699.001]
  • [Cites] Breast Cancer Res Treat. 2004 Feb;83(3):249-89 [14758095.001]
  • [Cites] Cancer. 2004 May 1;100(9):1833-42 [15112263.001]
  • [Cites] Mol Cell Endocrinol. 2004 Apr 30;219(1-2):151-60 [15149736.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):4030-9 [15173018.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33639-46 [15161930.001]
  • [Cites] Cytometry. 1983 Mar;3(5):323-7 [6188586.001]
  • [Cites] Annu Rev Biochem. 1983;52:537-79 [6137188.001]
  • [Cites] Cancer Res. 1986 Mar;46(3):1124-31 [3943090.001]
  • [Cites] Adv Exp Med Biol. 1985;191:763-73 [3832881.001]
  • [Cites] Eur J Cancer Clin Oncol. 1987 Jul;23(7):979-82 [2822427.001]
  • [Cites] Cancer Res. 1993 Jan 15;53(2):283-90 [8380254.001]
  • [Cites] Cancer Res. 1993 Feb 1;53(3):627-35 [8425198.001]
  • [Cites] Cancer Res. 1993 Jul 15;53(14):3229-32 [8324732.001]
  • [Cites] J Biol Chem. 1994 Nov 18;269(46):28523-6 [7961793.001]
  • [Cites] Cell Growth Differ. 1996 Mar;7(3):351-9 [8838865.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Mar;84(3):1116-21 [10084604.001]
  • [Cites] Mol Endocrinol. 1999 May;13(5):764-73 [10319326.001]
  • [Cites] J Biol Chem. 1999 Aug 6;274(32):22618-26 [10428842.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7947-53 [15520201.001]
  • [Cites] Mol Cancer Ther. 2005 Jan;4(1):33-41 [15657351.001]
  • [Cites] Mol Nutr Food Res. 2005 Feb;49(2):93-100 [15617098.001]
  • [Cites] Vitam Horm. 2005;71:201-37 [16112269.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D108-10 [16381825.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2815-25 [16510604.001]
  • [Cites] Curr Top Med Chem. 2006;6(3):203-15 [16515477.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5278-86 [16707453.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):7007-15 [16849545.001]
  • [Cites] Ann Oncol. 2006 Aug;17(8):1228-33 [16740599.001]
  • [Cites] Endocrinology. 2006 Sep;147(9):4056-66 [16809439.001]
  • [Cites] Clin Cancer Res. 2006 Nov 15;12(22):6652-62 [17121884.001]
  • [Cites] Mol Cancer Res. 2007 Jan;5(1):71-85 [17259347.001]
  • [Cites] BMC Cancer. 2007;7:59 [17407600.001]
  • [Cites] Breast Cancer Res Treat. 2007 Jul;104(1):109-14 [17061042.001]
  • [Cites] Cell Metab. 2007 Jul;6(1):13-24 [17618853.001]
  • [Cites] Int J Cancer. 2007 Oct 15;121(8):1779-85 [17594689.001]
  • [Cites] Cancer Lett. 2007 Oct 18;256(1):1-24 [17475399.001]
  • [Cites] Endocr Relat Cancer. 2007 Sep;14(3):549-67 [17914088.001]
  • [Cites] FASEB J. 2007 Dec;21(14):4013-27 [17660348.001]
  • [Cites] Eur J Cancer. 2008 Jan;44(1):73-83 [18035533.001]
  • [ErratumIn] Cancer Res. 2009 Feb 15;69(4):1695. Zhu, Yuelin [added]
  • (PMID = 18974135.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCATS NIH HHS / TR / UL1 TR000101; United States / NCI NIH HHS / CA / R01 CA096483; United States / NCI NIH HHS / CA / 1P30-CA51008-16; United States / NCI NIH HHS / CA / P30 CA051008; United States / NCI NIH HHS / BC / BC030280; United States / NCI NIH HHS / CA / R01 CA096483-01A1; United States / NCI NIH HHS / CA / T32 CA009686; United States / NCI NIH HHS / BC / BC051851
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / ESRRG protein, human; 0 / Receptors, Estrogen; 0 / Transcription Factor AP-1; 094ZI81Y45 / Tamoxifen; 17197F0KYM / afimoxifene
  • [Other-IDs] NLM/ NIHMS69287; NLM/ PMC2701641
  •  go-up   go-down


58. Wood WC: Should the use of contralateral prophylactic mastectomy be increasing as it is? Breast; 2009 Oct;18 Suppl 3:S93-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The choice of surgical procedure is primarily influenced by the recommendations of physicians and surgeons.
  • As smaller breast cancers are detected by improved breast screening, and larger breast cancers are reduced in size by neo-adjuvant chemo- and endocrine therapy, breast conservation therapy (BCT) has been applicable to more women.
  • No one would advocate CPM with the breast primary was to be treated by BCT.
  • The ability to better define inherited breast cancer risk by genetic analysis of BRCA1 or 2 mutations does identify a group of patients at greatly increased lifetime risk of contralateral breast cancer (CBC).
  • It appears that many physicians and surgeons believe the risk of contralateral breast cancer to be sufficiently high to justify advising CPM.
  • Invasive lobular carcinoma is considered by some physicians to represent an increased risk of contralateral cancer, but that has not proved to be correct.
  • Women with lobular carcinoma in situ or atypical ductal hyperplasia found at the time of their cancer diagnosis are sometimes advised to consider CPM.
  • Treatment with tamoxifen has shown a 50-75% reduction in risk from these tissue findings.
  • Chemotherapy for the primary breast cancer also lowers contralateral risk by about 20%.
  • The use of skin-sparing mastectomy has greatly reduced the incidence of any surgery needed for symmetry on the contralateral breast.
  • MRI used to "stage the breast" can raise questions by noting small foci of enhancement in the contralateral breast.
  • Some women elect CPM rather than biopsy or further imaging of the contralateral breast.
  • Its increase raises questions of the awareness of breast oncologists, medical and surgical, of the true risk data.
  • [MeSH-major] Breast Neoplasms / prevention & control. Mastectomy / adverse effects. Neoplasms, Second Primary / prevention & control
  • [MeSH-minor] Decision Making. Humans. Male. Risk Factors

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19914552.001).
  • [ISSN] 1532-3080
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


59. McLemore EC, Pockaj BA, Reynolds C, Gray RJ, Hernandez JL, Grant CS, Donohue JH: Breast cancer: presentation and intervention in women with gastrointestinal metastasis and carcinomatosis. Ann Surg Oncol; 2005 Nov;12(11):886-94
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer: presentation and intervention in women with gastrointestinal metastasis and carcinomatosis.
  • BACKGROUND: Breast cancer metastatic to the gastrointestinal tract or peritoneum is rare.
  • We reviewed the natural history of ductal and lobular carcinoma in women with breast cancer metastatic to the gastrointestinal tract, peritoneum, or both.
  • METHODS: We performed a retrospective review of all patients (1985-2000) with a pathologic diagnosis of breast cancer metastatic to the gastrointestinal tract or peritoneum.
  • The median age at initial breast cancer diagnosis was 55 years.
  • Infiltrating lobular carcinoma represented 34 (64%) of the 53 gastrointestinal metastases.
  • Advanced age at diagnosis and gastric metastases had a negative effect on survival, whereas treatment with systemic chemotherapy or tamoxifen had a positive effect on survival.
  • CONCLUSIONS: Gastrointestinal metastasis occurred more often in patients with invasive lobular carcinoma.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary. Carcinoma, Lobular / secondary. Gastrointestinal Neoplasms / secondary. Peritoneal Neoplasms / secondary

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16177864.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Horii R, Akiyama F, Kasumi F, Koike M, Sakamoto G: Spontaneous " healing" of breast cancer. Breast Cancer; 2005;12(2):140-4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous " healing" of breast cancer.
  • BACKGROUND: Healing is a phenomenon by which the intraductal component of breast cancer disappears and is replaced by fibrous tissue.
  • Focally localized healing often prevents confirmation of the continuity of intraductal carcinoma.
  • OBJECTIVE: To clarify the clinicopathological characteristics of breast cancer with healing.
  • PATIENTS AND METHODS: At our hospital, 308 patients (311 breasts) underwent breast conservation therapy without neoadjuvant chemotherapy for breast cancer in 2000.
  • We assessed the proportion and the characteristics of breast cancer with healing. RESULTS:.
  • (1) The proportion of breast cancer with healing was 7% (21/311). (2) In the 21 patients, the mean age was 59.2 years, and the mean diameter was 2.8 cm. (3) The histological type of the breast cancer varied: noninvasive ductal carcinoma in 2 cases, papillotubular carcinoma in 5, solid-tubular carcinoma in 8, scirrhous carcinoma in 5, invasive lobular carcinoma in 1, and Paget's disease in 1.
  • However in all cases, the histologic type of the intraductal carcinoma foci was the comedo/solid type and the nuclear grade of cancer cells was high. (4) In cases with healing, areas of healing were seen in an average of 5 (1-26) blocks, compared with intraductal carcinoma foci in 13 blocks (2-40).
  • CONCLUSION: The proportion of breast cancer cases with healing was 7% and these cases were intraductal carcinoma of the comedo/solid type, consisting of highly malignant cancer cells.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / therapy. Carcinoma / therapy. Neoplasm Regression, Spontaneous / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15858446.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


61. Mateş IN, Dinu D, Iosif C, Anghelescu L, Constantinoiu S: [Simultaneous bilateral breast carcinoma--case study and review of primitive bilateral breast cancer]. Chirurgia (Bucur); 2007 Jul-Aug;102(4):471-9
MedlinePlus Health Information. consumer health - Mastectomy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Simultaneous bilateral breast carcinoma--case study and review of primitive bilateral breast cancer].
  • [Transliterated title] Carcinom mamar bilateral, simultan. Studiu de caz şi review asupra cancerului mamar bilateral primitiv.
  • Bilateral breast cancer is uncommon and difficult to define because it may manifest as simultaneous, synchronous or metachronous tumours.
  • Following a right breast contusion, bilateral breast tumours were diagnosed in a 74 old female patient; the left one, neglected for 3 years, typically scirrous; the right one with cystic, pseudo-inflammatory appearance.
  • Sonography and fine-needle cytology concluded: left, carcinoma (T3bN1Mx); right, benign nodule with traumatic hematoma.
  • Three sessions of chemotherapy were followed by simultaneous left Madden mastectomy and right simple mastectomy (frozen sections negative for malignancy).
  • Histopathology: left, invasive lobular carcinoma (ypT4N0Mx); right, micropapillary invasive carcinoma mixed with adenoid cystic carcinoma.
  • Based on clinical, epidemiologic, morphologic and genetic evidence, bilateral breast cancers (synchronous or metachronous) are considered to be a special evolutive entity of breast cancer.
  • Our case suggests that, in the absence of risk factors for bilaterality of breast carcinoma: description of bilateral breast cancers based on diagnostic chronology of the two tumours is arbitrary; they may occur sporadically and have independent evolution; their biology rather resembles a multiple primitive malignancy than a true bilateral breast cancer.
  • [MeSH-major] Breast Neoplasms. Carcinoma. Mastectomy. Neoplasms, Multiple Primary
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Risk Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17966947.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Romania
  • [Number-of-references] 58
  •  go-up   go-down


62. Zagouri F, Sergentanis TN, Koulocheri D, Nonni A, Bousiotou A, Domeyer P, Michalopoulos NV, Dardamanis D, Konstadoulakis MM, Zografos GC: Bilateral synchronous breast carcinomas followed by a metastasis to the gallbladder: a case report. World J Surg Oncol; 2007;5:101
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral synchronous breast carcinomas followed by a metastasis to the gallbladder: a case report.
  • BACKGROUND: Breast cancer is usually associated with metastases to lungs, bones and liver.
  • Breast carcinoma metastasizing to the gallbladder is very rare.
  • CASE PRESENTATION: A 59-year-old woman presented with bilateral synchronous breast lesions.
  • A palpable, retroareolar solid lesion of diameter equal to 5 cm was present in the right breast, and a newly developed, non-palpable lesion with microcalcifications (diameter equal to 0.7 cm) was present in the upper outer quadrant of the left breast.
  • Modified radical mastectomy was performed on the right breast and lumpectomy after hook-wire localization was performed on the left breast, combined with lymph node dissection in both sides.
  • The pathological examination revealed invasive lobular carcinoma grade II in the right breast and invasive ductal carcinoma grade I in the left breast.
  • Chemotherapy, radiation therapy, trastuzumab and letrozole were appropriately administered.
  • At the 20th month after surgery however, the patient developed symptoms of cholecystitis and underwent cholecystectomy.
  • The histopathological examination revealed metastasis of the lobular carcinoma to the gallbladder.
  • CONCLUSION: This extremely rare case confirms on a single patient the results of large series having demonstrated the preferential metastasis of lobular breast cancer to the gallbladder.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary. Carcinoma, Lobular / secondary. Gallbladder Neoplasms / secondary. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Biopsy, Needle. Chemotherapy, Adjuvant. Cholecystectomy / methods. Female. Follow-Up Studies. Humans. Immunohistochemistry. Mastectomy, Modified Radical. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Risk Assessment. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 1989 Nov;42(11):1223-4 [2584434.001]
  • [Cites] J Surg Oncol. 1991 Mar;46(3):211-4 [1707119.001]
  • [Cites] Surgery. 1993 Oct;114(4):637-41; discussion 641-2 [8211676.001]
  • [Cites] Am Surg. 1996 Sep;62(9):745-7 [8751766.001]
  • [Cites] Cancer. 1950 Jan;3(1):74-85 [15405683.001]
  • [Cites] J Am Geriatr Soc. 2005 Nov;53(11):2041-3 [16274401.001]
  • [Cites] J Surg Oncol. 1986 Apr;31(4):240-2 [3724179.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2006;13(6):591-3 [17139439.001]
  • [Cites] Am J Gastroenterol. 2000 May;95(5):1379-81 [10811372.001]
  • [Cites] Rev Fac Cien Med Univ Nac Cordoba. 1999;56(2):123-7 [10883514.001]
  • [Cites] Eur J Cancer. 2004 Feb;40(3):336-41 [14746850.001]
  • [Cites] Br J Cancer. 1984 Feb;49(2):235-9 [6696823.001]
  • [Cites] Am J Epidemiol. 1986 Mar;123(3):532-43 [3946399.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2006 May;5(2):305-7 [16698597.001]
  • (PMID = 17848197.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2075501
  •  go-up   go-down


63. Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, Cushing-Haugen KL, Daling JR: Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA; 2003 Jun 25;289(24):3254-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between long durations and different regimens of hormone therapy and risk of breast cancer.
  • CONTEXT: Women using combined estrogen and progestin hormone replacement therapy (CHRT) have an increased risk of breast cancer; however, data on use for long durations and on risk associated with patterns of use are lacking.
  • OBJECTIVE: To evaluate relationships between durations and patterns of CHRT use and risk of breast cancer by histological type and hormone receptor status.
  • PARTICIPANTS: Nine hundred seventy-five women 65-79 years of age diagnosed with invasive breast cancer from April 1, 1997, through May 31, 1999 (histology: 196 lobular cases, 656 ductal cases, 114 cases with other histological type, and 9 cases with an unspecified histological type; estrogen receptor (ER)/progesterone receptor (PR) status: 646 ER+/PR+ cases, 147 ER+/PR- cases, and 101 ER-/PR- cases [6 ER-/PR+ cases and 75 cases with unknown ER/PR status were not included in the analyses herein]) and 1007 population controls.
  • MAIN OUTCOME MEASURES: Risks of invasive lobular, ductal, ER+/PR+, ER+/PR-, and ER-/PR- breast carcinomas.
  • RESULTS: Women using unopposed estrogen replacement therapy (ERT) (exclusive ERT use), even for 25 years or longer, had no appreciable increase in risk of breast cancer, although the associated odds ratios were not inconsistent with a possible small effect.
  • Ever users of CHRT (includes CHRT users who also had used ERT) had a 1.7-fold (95% confidence interval [CI], 1.3-2.2) increased risk of breast cancer, including a 2.7-fold (95% CI, 1.7-4.3) increased risk of invasive lobular carcinoma, a 1.5-fold (95% CI, 1.1-2.0) increased risk of invasive ductal carcinoma, and a 2.0-fold (95% CI, 1.5-2.7) increased risk of ER+/PR+ breast cancers.
  • The increase in risk was greatest in those using CHRT for longer durations (users for 5-14.9 years and >or=15 years had 1.5-fold [95% CI, 1.0-2.3] and 1.6-fold [95% CI, 1.0-2.6] increases in risk of invasive ductal carcinoma, respectively, and 3.7-fold [95% CI, 2.0-6.6] and 2.6-fold [95% CI, 1.3-5.3] increases in risk of invasive lobular carcinoma, respectively.
  • Risks of ER+/PR- and ER-/PR- tumors were not increased by use of any form of hormone replacement therapy; however, small numbers of these tumors limited power to detect possible associations.
  • CONCLUSION: These data suggest that use of CHRT is associated with an increased risk of breast cancer, particularly invasive lobular tumors, whether the progestin component was taken in a sequential or in a continuous manner.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] JAMA. 2003 Jun 25;289(24):3304-6 [12824214.001]
  • (PMID = 12824206.001).
  • [ISSN] 1538-3598
  • [Journal-full-title] JAMA
  • [ISO-abbreviation] JAMA
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA072787
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogens; 0 / Progestins; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


64. Khakpour N, Hunt KK, Kuerer HM, Yi M, Meric-Bernstam F, Ross MI, Lucci A: Sentinel lymph node dissection provides axillary control equal to complete axillary node dissection in breast cancer patients with lobular histology and a negative sentinel node. Am J Surg; 2005 Oct;190(4):598-601
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel lymph node dissection provides axillary control equal to complete axillary node dissection in breast cancer patients with lobular histology and a negative sentinel node.
  • OBJECTIVE: Invasive lobular carcinoma (ILC) presents special challenges to treating physicians because of the diffuse infiltrative growth pattern.
  • As sentinel lymph node dissection (SLND) is rapidly replacing axillary lymph node dissection (ALND) in the management of patients with early-stage breast cancer, we sought to evaluate the safety of SLND in providing axillary control in breast cancer patients with lobular histology and a negative sentinel node.
  • METHODS: We identified 239 patients with T1-2,N0,M0 lobular breast cancer from the prospective databases of 2 institutions; all were treated between March 1994 and December 2003.
  • There was no significant difference between the 2 groups with respect to tumor size, presence of lymphovascular invasion, estrogen receptor (ER)/progesterone receptor (PR) and HER-2/neu status, type of breast surgery, margin status, or nuclear grade.
  • Use of chemotherapy, radiation, and hormonal therapy was not significantly different between groups.
  • CONCLUSIONS: SLND provided axillary control equivalent to that of ALND for patients with lobular breast cancer.
  • SLND alone appears to be adequate axillary management of patients with lobular breast cancer and a negative sentinel node.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Lobular / pathology. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Axilla. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16164930.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Sasson AR, Fowble B, Hanlon AL, Torosian MH, Freedman G, Boraas M, Sigurdson ER, Hoffman JP, Eisenberg BL, Patchefsky A: Lobular carcinoma in situ increases the risk of local recurrence in selected patients with stages I and II breast carcinoma treated with conservative surgery and radiation. Cancer; 2001 May 15;91(10):1862-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lobular carcinoma in situ increases the risk of local recurrence in selected patients with stages I and II breast carcinoma treated with conservative surgery and radiation.
  • BACKGROUND: Lobular carcinoma in situ (LCIS) is a known risk factor for the development of invasive breast carcinoma.
  • However, little is known regarding the impact of LCIS in association with an invasive carcinoma on the risk of an ipsilateral breast tumor recurrence (IBTR) in patients who are treated with conservative surgery (CS) and radiation therapy (RT).
  • The purpose of this study was to examine the influence of LCIS on the local recurrence rate in patients with early stage breast carcinoma after breast-conserving therapy.
  • METHODS: Between 1979 and 1995, 1274 patients with Stage I or Stage II invasive breast carcinoma were treated with CS and RT.
  • The median follow-up time was 6.3 years.
  • LCIS was more likely to be associated with an invasive lobular carcinoma (30 of 59 patients; 51%) than with invasive ductal carcinoma (26 of 1125 patients; 2%).
  • Ipsilateral breast tumor recurrence (IBTR) occurred in 57 of 1209 patients (5%) without LCIS compared with 10 of 65 patients (15%) with LCIS (P = 0.001).
  • In both groups, the majority of recurrences were invasive.
  • Subsets of patients in which the presence of LCIS was associated with an increased risk of breast recurrence included tumor size < 2 cm (T1), age < 50 years, invasive ductal carcinoma, negative lymph node status, and the absence of any adjuvant systemic treatment (chemotherapy or hormonal therapy) (P < 0.001).
  • LCIS margin status, invasive lobular carcinoma histology, T2 tumor size, and positive axillary lymph nodes were not associated with an increased risk of breast recurrence in these women.
  • CONCLUSIONS: The authors conclude that the presence of LCIS significantly increases the risk of an ipsilateral breast tumor recurrence in certain subsets of patients who are treated with breast-conserving therapy.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma in Situ / pathology. Carcinoma, Lobular / pathology. Neoplasm Recurrence, Local / diagnosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11346867.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement